Heterocyclic compounds, their preparation and pharmaceutical use

Abstract

The present disclosure relates to heterocyclic compounds, their preparation methods, and pharmaceutical uses. Specifically, the present disclosure relates to heterocyclic compounds represented by general formula (I), their preparation methods, and pharmaceutical compositions containing such compounds, as well as their use as therapeutic agents, particularly as Nav inhibitors and in the preparation of medicaments for treating and / or alleviating pain and pain-related disorders. wherein, each group in general formula (I) is as defined in the specification. TIFF2025529841000455.tif4454

Description

[Technical Field]

[0001] The present disclosure belongs to the pharmaceutical field and relates to heterocyclic compounds, their preparation methods and pharmaceutical uses. In particular, the present disclosure relates to heterocyclic compounds represented by general formula (I), their preparation methods and pharmaceutical compositions containing such compounds, as well as their use as Nav inhibitors and in the preparation of medicaments for treating and / or alleviating pain and pain-related disorders. [Background technology]

[0002] Pain is a complex physiological and psychological activity and one of the most common clinical symptoms. The International Association for the Study of Pain defines pain as "an unpleasant and emotional sensation accompanied by actual or potential tissue damage, and is subjective." Pain can serve as a warning signal, alerting the body to potential danger and providing essential protection for the body's normal vital functions. At the same time, pain is also a common clinical symptom. Even after the external stimulus that caused the pain has disappeared, intense or persistent pain can cause physiological dysfunction and seriously affect the body's quality of life. Statistics show that approximately one-fifth of people worldwide suffer from moderate to severe chronic pain.

[0003] Pain originates from nociceptors in the peripheral nervous system. These free nerve endings are widely distributed throughout the body in the skin, muscles, joints, and visceral tissues. They convert perceived thermal, mechanical, or chemical stimuli into nerve impulses (action potentials), which are transmitted via afferent nerve fibers to their cell bodies in the dorsal root ganglia (DRG) and ultimately to higher nerve centers, resulting in a pain sensation. The generation and conduction of action potentials in neurons depend on voltage-gated sodium channels (Nav) on the cell membrane. When the cell membrane is depolarized, sodium ion channels are activated, allowing the influx of sodium ions, further depolarizing the cell membrane and generating an action potential. Therefore, inhibiting abnormal sodium ion channel activity contributes to the treatment and relief of pain.

[0004] Navs are a type of transmembrane ion channel protein. They consist of an α subunit with a molecular weight of 260 kD and a β subunit with a molecular weight of 30-40 kD. They can be classified into nine subtypes, Nav1.1 to Nav1.9, based on the α subunit. Different subtypes exhibit different tissue distributions and electrophysiological and pharmacological characteristics. Depending on whether they can be effectively inhibited by nanomolar tetrodotoxin (TTX), sodium ion channels can be classified as TTX-sensitive (TTX-S) or TTX-resistant (TTX-R). Nav1.1, Nav1.2, Nav1.3, and Nav1.7 are TTX-S types, and their encoding genes are located on human chromosomes 2q23-24. They are abundantly expressed in neurons. Nav1.5, Nav1.8, and Nav1.9 are TTX-R types, and their encoding genes are located on human chromosomes 3p21-24. Of these, Nav1.5 is primarily found in cardiac myocytes, while Nav1.8 and Nav1.9 are found in the peripheral nervous system. Nav1.4 and Nav1.6 are both TTX-S type and are abundant in skeletal muscle and the central nervous system, respectively. The local anesthetic lidocaine relieves pain by inhibiting Nav. Meanwhile, nonselective Nav inhibitors, such as lamotrigine, lacosamide, and mexiletine, have already been successfully used to treat chronic pain.

[0005] Nav1.8 is a TTX-R-type protein encoded by the SCN10A gene, is primarily present in trigeminal ganglion neurons and DRG neurons, and has the electrophysiological characteristics of slow inactivation and rapid recovery. In Nav1.8-expressing neurons, the rise of action potentials is primarily driven by Nav1.8 currents. In several models of neuropathic pain, nerve injury increases Nav1.8 expression levels in axons and neuronal cell bodies. The use of Nav1.8 antisense oligonucleotides significantly reduces pain by reducing Nav1.8 expression. In rats, intranasal injection of carrageenan increases Nav1.8 expression in DRG neurons. Nav1.8 knockout mice fail to exhibit normal visceral inflammatory pain. Gain-of-function mutations in the human Nav1.8 gene cause peripheral neuralgia. A series of animal experiments and human genetic evidence suggest that selective inhibition of Nav1.8 may be a novel analgesic therapy that can be used to treat various types of pain, including inflammatory pain, neuralgia, postoperative pain, and cancer pain.

[0006] Clinically used Nav inhibitors lack subtype selectivity and can only inhibit sodium ion channels expressed in the heart and central nervous system, resulting in a narrow therapeutic window and limited use. Because Nav1.8 is primarily distributed in the peripheral nervous system, selective inhibition of Nav1.8 can effectively reduce side effects. Therefore, there is a need to develop Nav1.8 inhibitors with higher activity, better selectivity, better pharmacokinetic properties, and fewer side effects.

[0007] Patent applications that have disclosed Nav1.8 inhibitor compounds include WO2021113627A1, WO2022256622A1, WO2022256676A1, WO2022256679A1, WO2022256842A1, and WO2022256702A1. Summary of the Invention

[0008] The present disclosure aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: [ka] Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R A are the same or different and each independently represent a deuterium atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , -S(=NR5 )NR 3 R 4 , -S(=NR 5 )R 6 , -S(=NR 5 )(O)NR 3 R 4 , -Si(O)NR 3 R 4 , -Si(R 6 )3, -OR 6 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a -C(O)-cycloalkyl group, a -C(O)-heterocyclyl group, an -alkylene-O-alkylene-cycloalkyl group, an -alkylene-O-cycloalkyl group, an -O-alkylene-heteroaryl group and an -O-alkylene-heterocyclyl group, wherein the alkyl group, alkoxy group, alkoxyalkyl group, alkenyl group, alkynyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, heteroaryl group, cycloalkylalkyl group and heterocyclylalkyl group each independently and optionally may be selected from the group consisting of 01 is replaced by Cy is a cycloalkyl group or a heterocyclyl group, and the cycloalkyl group and the heterocyclyl group are each independently optionally substituted with one or more substituents selected from deuterium, halogen, hydroxy, cyano, oxo, amino, -NH alkyl, -N(alkyl), acetyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups; Each R 3 , R 4 and R 5 are the same or different and each independently represent a hydrogen atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, or NR 20 R 21 , C(O)NR 20 R 21 , N.R. 22 C(O)R 23, C(O)R 23 , C(O)OR 23 ,OC(O)R 23 , S(O) v R 23 , S(O) v OR 23 , OS(O) v R 23 , S(O) v NR 20 R 21 , OR 23 , a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group are each independently optionally selected from one or more R 01 is replaced by Or, R 3 , R 4 together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R 01 is replaced by Each R 6 , R 7 and R 8 are the same or different and each independently represent a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, or NR 20 R 21 , C(O)NR 20 R 21 , N.R. 22 C(O)R 23 , C(O)R 23 , C(O)OR 23 ,OC(O)R 23 , S(O) v R 23 , S(O) v OR 23 , OS(O) v R 23 , S(O) v NR 20 R 21 , OR 23, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an aryl group, and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, cycloalkylalkyl group, heterocyclylalkyl group, aryl group, and heteroaryl group are each independently optionally selected from one or more R 01 is replaced by Each R 01 are the same or different and each independently represent a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, ═CR 7a R 8a , -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , -S(=NR 5 )NR 3 R 4 , -S(=NR 5 )R 6 , -S(=NR 5 )(O)NR 3 R 4 , -Si(O)NR 3 R 4 , -OR 6 , -Si(R 6a )3, -O-alkylene-heteroaryl and -O-alkylene-heterocyclyl groups, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from deuterium, halogen, hydroxy, cyano, oxo, amino, -NHalkyl, -N(alkyl), acetyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups; Each R 6a , R 7a and R 8a are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, a cycloalkyl group and a heterocyclyl group; X is O or S; R a and Rb are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, a deuterated alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a deuterated alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the cycloalkyloxy group and the heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by However, R a and R b is not hydrogen at the same time, R c and R d are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the cycloalkyloxy group and the heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Or, R a , R b together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R c , R d together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group may each independently optionally be one or more R 02 is replaced by R eis selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a deuterated alkyl group, a deuterated alkoxy group and a hydroxyalkyl group; Each R 02 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; Each R 20 , R 21 and R 22 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; Each R 23 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; X 1 is CR X1 or N, X 2 is CRX2 or N, X 3 is CR X3 or N, X 4 is CR X4 or N, X 5 is CR X5 or N, X 1 , X 2 , X 3 , X 4 and X 5 is not N at the same time, R X1 , R X2 , R X3 , R X4 and R X5 are the same or different and each independently represent a hydrogen atom, a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH2) n -cycloalkyl group, -O-(CH2) s -heterocyclyl groups, aryl groups and heteroaryl groups, wherein the alkyl groups, alkoxy groups, alkenyl groups, alkynyl groups, cycloalkyl groups, heterocyclyl groups, aryl groups and heteroaryl groups are each independently optionally selected from one or more R 03 is replaced by Each R 03 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; each v is the same or different and is independently selected from 0, 1, and 2; n is chosen from 0, 1, 2, 3, 4 and 5, s is chosen from 0, 1, 2, 3, 4 and 5, and r is chosen from 0, 1, 2, 3, 4 and 5, however, [ka] teeth [ka] isn't it.

[0009] The present disclosure aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: [ka] Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R A are the same or different and each independently represent a deuterium atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5-NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , -S(=NR 5 )NR 3 R 4 , -S(=NR 5 )R 6 , -S(=NR 5 )(O)NR 3 R 4 , -Si(O)NR 3 R 4 , -Si(R 6 )3, -OR 6 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a -C(O)-cycloalkyl group, a -C(O)-heterocyclyl group, an -alkylene-O-alkylene-cycloalkyl group, an -alkylene-O-cycloalkyl group, an -O-alkylene-heteroaryl group and an -O-alkylene-heterocyclyl group, wherein the alkyl group, alkoxy group, alkoxyalkyl group, alkenyl group, alkynyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, heteroaryl group, cycloalkylalkyl group and heterocyclylalkyl group each independently and optionally may be selected from the group consisting of 01 is replaced by Cy is a cycloalkyl group or a heterocyclyl group, and the cycloalkyl group and the heterocyclyl group are each independently optionally substituted with one or more substituents selected from deuterium, halogen, hydroxy, cyano, oxo, amino, -NH alkyl, -N(alkyl), acetyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups; Each R3 , R 4 and R 5 are the same or different and each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, or NR 20 R 21 , C(O)NR 20 R 21 , N.R. 22 C(O)R 23 , C(O)R 23 , C(O)OR 23 ,OC(O)R 23 , S(O) v R 23 , S(O) v OR 23 , OS(O) v R 23 , S(O) v NR 20 R 21 , OR 23 , a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group are each independently optionally selected from one or more R 01 is replaced by Or, R 3 , R 4 together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R 01 is replaced by Each R 6 , R 7 and R 8 are the same or different and each independently represent a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, or NR 20 R 21 , C(O)NR 20 R 21 , N.R. 22 C(O)R 23 , C(O)R 23 , C(O)OR 23 ,OC(O)R 23 , S(O) v R 23 , S(O)v OR 23 , OS(O) v R 23 , S(O) v NR 20 R 21 , OR 23 , a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an aryl group, and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, cycloalkylalkyl group, heterocyclylalkyl group, aryl group, and heteroaryl group are each independently optionally selected from one or more R 01 is substituted with a group selected from Each R 01 are the same or different and each independently represent a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, ═CR 7a R 8a , -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , -S(=NR 5 )NR 3 R 4 , -S(=NR 5 )R 6 , -S(=NR 5 )(O)NR 3 R 4 , -Si(O)NR 3 R 4 , -OR 6 , -Si(R 6a )3, -O-alkylene-heteroaryl and -O-alkylene-heterocyclyl groups, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from deuterium, halogen, hydroxy, cyano, oxo, amino, -NHalkyl, -N(alkyl), acetyl, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups; Each R 6a , R 7a and R 8a are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, and a heterocyclyl group; X is O or S; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by However, R a and R b is not hydrogen at the same time, R c and R d are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Or, R a , R b together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R c , R d together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group may each independently optionally be one or more R 02 is replaced by R eis selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group, Each R 02 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; Each R 20 , R 21 and R 22 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; Each R 23 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; X 1 is CR X1 or N, X 2 is CR X2 or N, X 3 is CR X3 or N, X 4 is CR X4 or N, X 5 is CR X5 or N, X 1 , X 2 , X 3 , X 4 and X 5 is not N at the same time, R X1 , R X2 , R X3 , R X4 and R X5 are the same or different and each independently represent a hydrogen atom, a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH2) n -cycloalkyl group, -O-(CH2) s -heterocyclyl, aryl and heteroaryl groups, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally selected from one or more R 03 is replaced by Each R 03 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; each v is the same or different and is independently selected from 0, 1, and 2; n is chosen from 0, 1, 2, 3, 4 and 5, s is chosen from 0, 1, 2, 3, 4 and 5, and r is chosen from 0, 1, 2, 3, 4 and 5, however, [ka] teeth [ka] isn't it.

[0010] The present disclosure aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: [ka] Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R A are the same or different and each independently represent a deuterium atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, an alkynyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5)NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , -S(=NR 5 )NR 3 R 4 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkynyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently and optionally may be selected from the group consisting of one or more R 01 is replaced by Cy is a cycloalkyl group or a 3- to 4-membered heterocyclyl group, and the cycloalkyl group or the 3- to 4-membered heterocyclyl group is each independently optionally substituted with one or more substituents selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group; Each R 3 , R 4 and R 5 are the same or different and each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, or NR 20 R 21 , C(O)NR 20 R 21 , N.R. 22 C(O)R 23 , C(O)R 23 , C(O)OR 23 ,OC(O)R 23 , S(O) v R 23 , S(O) v OR 23 , OS(O) v R 23 , S(O) v NR 20 R 21 , N.R. 22 S(O) v R 23, OR 23 , a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group are each independently optionally selected from one or more R 01 is replaced by Or, R 3 , R 4 together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R 01 is replaced by Each R 6 , R 7 and R 8 are the same or different and each independently represent a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, or NR 20 R 21 , C(O)NR 20 R 21 , N.R. 22 C(O)R 23 , C(O)R 23 , C(O)OR 23 ,OC(O)R 23 , S(O) v R 23 , S(O) v OR 23 , OS(O) v R 23 , S(O) v NR 20 R 21 , N.R. 22 S(O) v R 23 , OR 23, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, cycloalkylalkyl group, heterocyclylalkyl group, aryl group, and heteroaryl group are each independently optionally substituted with one or more substituents selected from a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an oxo group, an amino group, -NH alkyl group, -N(alkyl)2, an acetyl group, an alkyl group, alkenyl group, alkynyl group, alkoxy group, haloalkyl group, haloalkoxy group, hydroxyalkyl group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group; Each R 01 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, and a heterocyclyl group; X is O or S; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by However, R a and R b is not hydrogen at the same time, R c and R dare the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Or, R a , R b together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R c , R d together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group may each independently optionally be one or more R 02 is replaced by R e is selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group, Each R 02 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; Each R 20 , R 21 and R 22are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; Each R 23 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; X 1 is CR X1 or N, X 2 is CR X2 or N, X 3 is CR X3 or N, X 4 is CR X4 or N, X 5 is CR X5 or N, X 1 , X 2 , X 3 , X 4 and X 5 is not N at the same time, R X1 , R X2 , R X3 , R X4 and R X5are the same or different and each independently represent a hydrogen atom, a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH2) n -cycloalkyl group, -O-(CH2) s -heterocyclyl, aryl and heteroaryl groups, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally selected from one or more R 03 is replaced by Each R 03 are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; each v is the same or different and is independently selected from 0, 1, and 2; n is chosen from 0, 1, 2, 3, 4 and 5, s is chosen from 0, 1, 2, 3, 4 and 5, and r is chosen from 0, 1, 2, 3, 4 and 5, however, [ka] teeth [ka] isn't it.

[0011] The present disclosure aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: [ka] Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R Aare the same or different and each independently represent a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by Cy is a cycloalkyl group or a 3- to 4-membered heterocyclyl group, and the cycloalkyl group or the 3- to 4-membered heterocyclyl group is each independently optionally substituted with one or more substituents selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group; R 3 , R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group each independently optionally include one or more R 01 is replaced by Or, R 3 , R 4 together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R 01 is replaced by R 6 , R 7 and R 8 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, cycloalkyl group, heterocyclyl group, cycloalkylalkyl group, heterocyclylalkyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more substituents selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH alkyl group, -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclylalkyl group, an aryl group and a heteroaryl group; R 01 are each independently selected from halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, and a heterocyclyl group; X is O or S; R a and R b are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by However, R a and R b is not hydrogen at the same time, R c and R d are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Or, R a , R b together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R c , R dtogether with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group may each independently optionally be one or more R 02 is replaced by R e is selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group, R 02 are each independently selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; X 1 is CR X1 or N, X 2 is CR X2 or N, X 3 is CR X3 or N, X 4 is CR X4 or N, X 5 is CR X5 or N, X 1 , X 2 , X 3 , X 4 and X 5 is not N at the same time, R X1 , R X2 , R X3 , R X4 and R X5 are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH2) n -cycloalkyl group, -O-(CH2) s-heterocyclyl, aryl and heteroaryl groups, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally selected from one or more R 03 is replaced by R 03 are each independently selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; v is chosen from 0, 1 and 2, n is chosen from 0, 1, 2, 3, 4 and 5, s is chosen from 0, 1, 2, 3, 4 and 5, and r is chosen from 0, 1, 2, 3, 4 and 5, however, [ka] teeth [ka] isn't it.

[0012] The present disclosure aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: [ka] Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R A are the same or different and each independently represent a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5)R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R 3 , R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group each independently optionally include one or more R 01 is replaced by Or, R 3 , R 4 together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R 01 is replaced by R 6 , R 7 and R 8are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R 01 are each independently selected from halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, and a heterocyclyl group; X is O or S; R a and R b are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by However, R a and R b is not hydrogen at the same time, R c and R d are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Or, R a, R b together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R c , R d together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group may each independently optionally be one or more R 02 is replaced by R e is selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group, R 02 are each independently selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; X 1 is CR X1 or N, X 2 is CR X2 or N, X 3 is CR X3 or N, X 4 is CR X4 or N, X 5 is CR X5 or N, X 1 , X 2 , X 3 , X 4 and X 5 is not N at the same time, R X1 , R X2 , R X3 , R X4 and R X5are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH2) n -cycloalkyl group, -O-(CH2) s -heterocyclyl, aryl and heteroaryl groups, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally selected from one or more R 03 is replaced by R 03 are each independently selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; v is chosen from 0, 1 and 2, n is chosen from 0, 1, 2, 3, 4 and 5, s is chosen from 0, 1, 2, 3, 4 and 5, and r is chosen from 0, 1, 2, 3, 4 and 5, however, [ka] teeth [ka] isn't it.

[0013] The present disclosure aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: [ka] Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R Aare the same or different and each independently represent a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -P(O)R 7 R 8 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R 3 , R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclyl group, the aryl group and the heteroaryl group each independently optionally include one or more R 01 is replaced by Or, R 3 , R 4 together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R 01 is replaced by R 6 , R 7 and R 8are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; R 01 are each independently selected from a halogen atom, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2, an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, a cycloalkyl group, and a heterocyclyl group; X is O or S; R a and R b are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by However, R a and R b is not hydrogen at the same time, R c and R d are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the cycloalkyl group, heterocyclyl group, cycloalkyloxy group and heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Or, R a , R btogether with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R c , R d together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group may each independently optionally be one or more R 02 is replaced by R e is selected from a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group, R 02 are each independently selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; X 1 is CR X1 or N, X 2 is CR X2 or N, X 3 is CR X3 or N, X 4 is CR X4 or N, X 5 is CR X5 or N, X 1 , X 2 , X 3 , X 4 and X 5 is not N at the same time, R X1 , R X2 , R X3 , R X4 and R X5are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH2) n -cycloalkyl group, -O-(CH2) s -heterocyclyl, aryl and heteroaryl groups, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally selected from one or more R 03 is replaced by R 03 are each independently selected from a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; v is chosen from 0, 1 and 2, n is chosen from 0, 1, 2, 3, 4 and 5, s is chosen from 0, 1, 2, 3, 4 and 5, and r is chosen from 0, 1, 2, 3, 4 and 5, however, [ka] teeth [ka] isn't it.

[0014] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein R e is a hydrogen atom, halogen, hydroxyl group, cyano group and C 1-6 alkyl groups, preferably R e is a hydrogen atom.

[0015] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein X 1 is N and X 2 is CR X2 and X 3 is CR X3 and X 4 is CR X4 and X 5 is CR X5 or X 2 is N and X 1 is CR X1 and X 3 is CR X3 and X 4 is CR X4 and X 5 is CR X5 or X 3 is N and X 1 is CR X1 and X 2 is CR X2 and X 4 is CR X4 and X 5 is CR X5 or X 1 is N and X 3 is N and X 2 is CR X2 and X 4 is CR X4 and X 5 is CR X5 or X 2 is N and X 4 is N and X 1 is CR X1 and X 3 is CR X3 and X 5 is CR X5 or X 1 is CR X1 and X 2 is CR X2 and X 3 is CR X3 and X 4 is CR X4 and X 5 is CR X5 and R X1, R X2 , R X3 , R X4 and R X5 is as defined in general formula (I), and preferably X 1 is CR X1 and X 2 is CR X2 and X 3 is CR X3 and X 4 is CR X4 and X 5 is CR X5 and R X1 , R X2 , R X3 , R X4 and R X5 is as defined in general formula (I), more preferably X 1 is CR X1 and X 2 is CR X2 and X 3 is CR X3 and X 4 is CH and X 5 is CH and R X1 , R X2 and R X3 are the same or different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 selected from a hydroxyalkyl group, a 3- to 8-membered cycloalkyl group, a 4- to 7-membered heterocyclyl group, a 3- to 8-membered cycloalkyloxy group, and a 4- to 7-membered heterocyclyloxy group, and the 3- to 8-membered cycloalkyl group, the 4- to 7-membered heterocyclyl group, the 3- to 8-membered cycloalkyloxy group, and the 4- to 7-membered heterocyclyloxy group are each independently optionally selected from one or more R 03 is replaced by R 03 are each independently a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, or C 1-6 Alkyl group, halo C 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6is selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group, and most preferably, X 1 is CR X1 and X 2 is CR X2 and X 3 is CR X3 and X 4 is CH and X 5 is CH and R X1 , R X2 and R X3 are the same or different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl and Halo C 1-6 The alkoxy group is selected from the group consisting of alkoxy groups.

[0016] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein: [ka] teeth [ka] Selected from R a , R b , R c , R d and X are as defined in general formula (I), preferably [ka] teeth [ka] X is O or S, and R a and R b are different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6R is selected from an alkoxy group and a 3- to 10-membered cycloalkyl group; c and R d are different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 It is selected from an alkoxy group and a 3- to 10-membered cycloalkyl group, and more preferably [ka] teeth [ka] and R a and R b are different and each independently represent a hydrogen atom, C 1-6 Alkyl groups and C 1-6 haloalkyl groups, R c and R d are different and each independently represent a hydrogen atom, C 1-6 Alkyl groups and C 1-6 It is selected from haloalkyl groups.

[0017] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein: [ka] teeth [ka] and R a and R b are the same or different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, halo C 1-6 R is selected from alkyl groups and 3- to 10-membered cycloalkyl groups; c and R d are different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, halo C 1-6 selected from alkyl groups and 3- to 10-membered cycloalkyl groups, In some embodiments, the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein: [ka] teeth [ka] and R a and R b are different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, halo C 1-6 R is selected from alkyl groups and 3- to 10-membered cycloalkyl groups; c and R d are the same or different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl group, halo C 1-6 It is selected from alkyl groups and 3- to 10-membered cycloalkyl groups.

[0018] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof:

[0019] [ka] Among them, R a and R b are different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, or C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6hydroxyalkyl group, 3- to 10-membered cycloalkyl group, 3- to 10-membered heterocyclyl group, 3- to 10-membered cycloalkyloxy group and 3- to 10-membered heterocyclyloxy group, wherein the 3- to 10-membered cycloalkyl group, 3- to 10-membered heterocyclyl group, 3- to 10-membered cycloalkyloxy group and 3- to 10-membered heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by R c and R d are different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an amino group, or C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 hydroxyalkyl group, 3- to 10-membered cycloalkyl group, 3- to 10-membered heterocyclyl group, 3- to 10-membered cycloalkyloxy group and 3- to 10-membered heterocyclyloxy group, wherein the 3- to 10-membered cycloalkyl group, 3- to 10-membered heterocyclyl group, 3- to 10-membered cycloalkyloxy group and 3- to 10-membered heterocyclyloxy group may optionally be selected from the group consisting of one or more R 02 is replaced by Ring A, R A , R', X, R X1 , R X2 , R X3 , R 02 and r are as defined in general formula (I).

[0020] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II') or a pharmaceutically acceptable salt thereof: [ka] Among them, R 3a represents a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, OR 6, a cycloalkyl group, and a heterocyclyl group, wherein the alkyl group, the cycloalkyl group, and the heterocyclyl group are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, oxo, amino, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, and heterocyclyl groups; r-1 is 0, 1, 2, 3 or 4; Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 4 , R 5 and R 6 is as defined in general formula (II).

[0021] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof, [ka] wherein r-1 is 0, 1, 2, 3 or 4; Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 and R 5 is as defined in general formula (II).

[0022] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, [ka] Among them, t is chosen from 0, 1, 2, 3 and 4, Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 and R X3 is as defined in general formula (II).

[0023] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II) or (III) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III-1) or a pharmaceutically acceptable salt thereof: [ka] Among them, t is chosen from 0, 1, 2, 3 and 4, Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 and R X3 is as defined in general formula (II).

[0024] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 1A and R 2A are the same or different and each independently represent a hydrogen atom or R A and R 3A is R A and R a , R b , R c , R d , R X1 , RX2 , R X3 , R' and R A is as defined in general formula (II).

[0025] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 1A and R 2A are the same or different and each independently represent a hydrogen atom or R A and R 3A is F, Cl, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, an alkynyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5-OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , -S(=NR 5 )NR 3 R 4 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkynyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently and optionally may be selected from the group consisting of one or more R 01 is replaced by R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R A , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 01 and v are as defined in general formula (II).

[0026] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -P(O)R 7 R 8 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R 3A is a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 01 and v are as defined in general formula (I), preferably R a , R b , R c , R d is as defined in general formula (II).

[0027] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -P(O)R 7 R 8 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R 3A is a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4, -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 01 and v are as defined in general formula (I), preferably R a , R b , R c , R d is as defined in general formula (II).

[0028] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R 3A is a hydroxy group, an amino group, C 1-6Alkyl group, C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene-NH2, -OC 1-6 Alkylene -NH2, -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , a 3- to 8-membered cycloalkyl group, a 3- to 8-membered heterocyclyl group, a phenyl group, a 5- or 6-membered heteroaryl group, and -OC 1-6 alkylene-5 or 6-membered heteroaryl groups, 1-6 The alkylene group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered heterocyclyl group, the phenyl group, and the 5- or 6-membered heteroaryl group each independently optionally may be one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH C 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 R is selected from the group consisting of a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; 3 , R 4 , R 5 and R 6 is as defined in general formula (I), In some embodiments, R 3A is an amino group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene -NH2, -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR6 , a 3- to 8-membered cycloalkyl group and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 8-membered cycloalkyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH C 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 R is selected from the group consisting of a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; 3 , R 4 , R 5 and R 6 is as defined in general formula (I), In some embodiments, R 3A is an amino group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene -NH2, -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , a 3- to 6-membered cycloalkyl group and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 6-membered cycloalkyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, an amino group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, R 3 , R 4 , R 5 and R6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R 3A is an amino group, C 1-6 hydroxyalkyl groups, [ka] Among them, G 1 is a nitrogen atom or CR G and G 2 is a nitrogen atom or CR G and R A4 is a hydrogen atom, a hydroxyl group, C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, R 3 , R 4 , R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and R 01 is a hydroxy group, a cyano group, an amino group and C 1-6 hydroxyalkyl groups, and each R G and R N are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, t is selected from 0, 1, 2 and 3, u1 is selected from 0, 1 and 2, u2 is selected from 0, 1, 2 and 3, and u3 is selected from 1, 2 and 3; In some embodiments, R 3A is an amino group, [ka] In some embodiments, R 3A teeth, [ka] Selected from In embodiments, R 3A is an amino group, [ka] Selected from.

[0029] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R 3A is C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -NR 3 R 4 , -C 1-6 Alkylene-NR 3 R 4 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 10-membered cycloalkyl group, the 3- to 10-membered heterocyclyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, R 3 and R 4 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, In some embodiments, R 3A is C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 alkylene-NH2, -C(O)NR5-OR6, a 3- to 6-membered cycloalkyl group and a 5- or 6-membered heteroaryl group, 1-6The alkylene group, the 3- to 6-membered cycloalkyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R 3A Ha-C 1-6 Alkylene -NH2 or -C(O)NR 5 -OR 6 and the above C 1-6 The alkylene group may optionally be one or more R 01 is replaced by R 01 are each independently a hydroxy group and C 1-6 hydroxyalkyl groups, R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 It is an alkyl group.

[0030] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II) or (IV) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5)R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -P(O)R 7 R 8 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R A4 is selected from a hydrogen atom, a hydroxy group, an alkyl group and a hydroxyalkyl group, u1 is selected from 0, 1, 2 and 3, u2 is selected from 0, 1, 2 and 3, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 01 and v are as defined in general formula (I), preferably R a , R b , R c , R d is as defined in general formula (II).

[0031] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (IV) or (V) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, [ka] Among them, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V).

[0032] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (V), (V-1), or (V-2), or a pharmaceutically acceptable salt thereof, wherein R A4 is a hydrogen atom, C 1-6 Alkyl groups and C 1-6 It is selected from hydroxyalkyl groups, and is preferably a hydrogen atom.

[0033] In some embodiments of the present disclosure, the compound is represented by the above general formula (V), (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, wherein u1 is selected from 0, 1 and 2, and u2 is selected from 0, 1 and 2, preferably u1 is 0 or 1, and u2 is 0 or 1, more preferably u1 is 0, and u2 is 1.

[0034] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (V), (V-1), or (V-2), or a pharmaceutically acceptable salt thereof, wherein R A4 is a hydrogen atom, u1 is selected from 0, 1 and 2, and u2 is selected from 0, 1 and 2.

[0035] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VI') or a pharmaceutically acceptable salt thereof: [ka] Among them, Q is CR 5A , N and N + -O - Selected from R 5A is R 1A and R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 and R 5 is as defined in general formula (IV).

[0036] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), or (VI') or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VI'-1) or a pharmaceutically acceptable salt thereof: [ka] Among them, Q is CR 5A , N and N + -O - Selected from R 5A is R 1A and R C is R 23 OR 23 and R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , RX3 , R 3 , R 5 and R 23 is as defined in general formula (IV).

[0037] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI'-1) or a pharmaceutically acceptable salt thereof, wherein R C is C 1-8 Alkyl group, C 1-8 In some embodiments, R C is C 1-8 is an alkoxy group, and in some embodiments, R C is an isopropoxy group or an n-hexyloxy group.

[0038] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (IV), or (VI') or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VI) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 3a represents a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, OR 6 , a cycloalkyl group, and a heterocyclyl group, wherein the alkyl group, the cycloalkyl group, and the heterocyclyl group are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, oxo, amino, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, and heterocyclyl groups; R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 4 , R 5 and R6 is as defined in general formula (IV).

[0039] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II') or (VI) or a pharmaceutically acceptable salt thereof, wherein R 3a is a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Hydroxyalkyl group, OR 6 , 3- to 6-membered cycloalkyl groups and 3- to 6-membered cycloalkyl groups 1-6 alkyl groups, R 6 is a hydrogen atom, C 1-6 Alkyl groups, 3- to 6-membered cycloalkyl groups and 3- to 6-membered cycloalkyl groups 1-6 selected from alkyl groups, In some embodiments, R 3a is a hydrogen atom, C 1-6 Alkyl group, C 1-6 In some embodiments, R 3a is a hydrogen atom, C 1-6 Alkyl groups and C 1-6 In some embodiments, R 3a is a hydrogen atom, C 1-6 In some embodiments, R 3a is a hydrogen atom or C 1-6 is an alkyl group, In some embodiments, R 3a is selected from a hydrogen atom, a methyl group, an ethyl group, a methoxy group, and a cyclopropyl group, and in some embodiments, R 3a is selected from a hydrogen atom, a methyl group, an ethyl group, and a cyclopropyl group, and in some embodiments, R 3a is a hydrogen atom, and in some embodiments, R 3a represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, [ka] Selected from.

[0040] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II-1) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VII') or a pharmaceutically acceptable salt thereof: [ka] Among them, Q is CR 5A , N and N + -O - Selected from R 5A is R 1A and R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 and R 5 is as defined in general formula (IV).

[0041] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II-1), (IV) or (VII') or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VII) or a pharmaceutically acceptable salt thereof: [ka] Among them, R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 and R 5 is as defined in general formula (IV).

[0042] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (VIII) or a pharmaceutically acceptable salt thereof: [ka] Among them, Q is CR 5A , N and N + -O - Selected from R 5A is R 1A and R 1A , R 2A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 and R 4 is as defined in general formula (IV).

[0043] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI'), (VI'-1), (VII'), or (VIII) or a pharmaceutically acceptable salt thereof, wherein Q is N or CR 5A and R 5A is R 1A and R 1A is as defined in general formula (IV), and in some embodiments, Q is N, and in some embodiments, Q is CR 5A and R 5A is R 1A and R 1A is as defined in general formula (IV), and in some embodiments, Q is N or CF.

[0044] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI'), (VI'-1), (VII'), or (VIII) or a pharmaceutically acceptable salt thereof, wherein R 5A is a hydrogen atom, halogen, C 1-6 Alkyl group, C 1-6Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 In some embodiments, R is selected from a hydroxyalkyl group, a 3- to 6-membered cycloalkyl group, and a 3- to 6-membered heterocyclyl group. 5A is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, and in some embodiments, R 5A is halogen, and in some embodiments, R 5A is F.

[0045] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an amino group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl groups and C 1-6 hydroxyalkoxy groups, preferably R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, more preferably R 1A and R 2A are both hydrogen atoms.

[0046] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R a is a hydrogen atom, halogen, C1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 In some embodiments, R is selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, and a 3- to 10-membered heterocyclyl group. a is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, and in some embodiments, R a is C 1-6 Alkyl or halo C 1-6 is an alkyl group, and in some embodiments, R a is CH3 or CF3, In some embodiments, R a is C 1-6 is an alkyl group, and in some embodiments, R a is selected from CH, a deuterated methyl group, and CF; in some embodiments, R a is CH or a deuterated methyl group, and in some embodiments, R a is CH3.

[0047] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R b is a hydrogen atom, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 In some embodiments, R is selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, and a 3- to 10-membered heterocyclyl group. b is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, and in some embodiments, Rb is C 1-6 Alkyl or halo C 1-6 is an alkyl group, and in some embodiments, R b is selected from CH, a deuterated methyl group, and CF; in some embodiments, R b is CH or CF, and in some embodiments, R b Halo C 1-6 is an alkyl group, and in some embodiments, R b is CF3.

[0048] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R c is a hydrogen atom, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 is selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, and a 3- to 10-membered heterocyclyl group, and preferably R c is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, more preferably R c is a hydrogen atom or C 1-6 alkyl group, most preferably R c is a hydrogen atom or CH3, and in some embodiments, R c is selected from a hydrogen atom, CH3, a deuterated methyl group and CF3.

[0049] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R d is a hydrogen atom, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 is selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, and a 3- to 10-membered heterocyclyl group, and preferably R d is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, more preferably R d is a hydrogen atom or C 1-6 alkyl group, more preferably R d is a hydrogen atom or CH3, and in some embodiments, R d is selected from a hydrogen atom, CH, a deuterated methyl group, and CF; in some embodiments, R d is selected from a hydrogen atom, CH3 and CD3.

[0050] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein R a and R b are the same or different and each independently represent a hydrogen atom, C 1-6 Alkyl and Halo C 1-6 alkyl groups, and in some embodiments, R a and R b are the same or different and each independently C 1-6 Alkyl or halo C 1-6 is an alkyl group, and in some embodiments, R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and in some embodiments, Ra is CH3 and R b is CF3, In some embodiments, R a and R b are the same or different and each independently selected from a hydrogen atom, CH, a deuterated methyl group, and CF; in some embodiments, R a and R b are the same or different and are each independently selected from a hydrogen atom, CH3 and CF3; In some embodiments, R a and R b are the same or different and each independently C 1-6 is an alkyl group, and in some embodiments, R a and R b are the same or different and each independently represent halo C 1-6 It is an alkyl group.

[0051] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R a and R b are different and each independently represent a hydrogen atom, C 1-6 Alkyl and Halo C 1-6 alkyl groups, preferably R a and R b are different and independently C 1-6 Alkyl or halo C 1-6 alkyl group, more preferably R a is C 1-6 is an alkyl group, and R b Halo C 1-6 alkyl group, most preferably R a is CH3 and R b is CF3, In some embodiments, R a and R bare different and each independently selected from a hydrogen atom, CH, a deuterated methyl group, and CF; in some embodiments, R a and R b are different and are each independently selected from a hydrogen atom, CH3, and CF3; In some embodiments, R a and R b are different and independently C 1-6 is an alkyl group, and in some embodiments, R a and R b are different and independently halo C 1-6 It is an alkyl group.

[0052] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R a Halo C 1-6 is an alkyl group, and R b is a hydrogen atom, and in some embodiments, R a Halo C 1-6 is an alkyl group, and R b is C 1-6 is an alkyl group, and in some embodiments, R a is CF3 and R b is CH3, In some embodiments, R a is a hydrogen atom, and R b Halo C 1-6 is an alkyl group, and in some embodiments, R a is a hydrogen atom, and R b is C 1-6 is an alkyl group, and in some embodiments, R a is C 1-6 is an alkyl group, and R b is a hydrogen atom.

[0053] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein R c and R d are the same or different and each independently represent a hydrogen atom, C 1-6 In some embodiments, R c and R d are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, and in some embodiments, R c is a hydrogen atom, and R d is CH3, In some embodiments, R c and R d are the same or different and each independently selected from a hydrogen atom, CH and a deuterated methyl group; in some embodiments, R c and R d are the same or different and each independently represent a hydrogen atom or CH; in some embodiments, R c and R d are both hydrogen atoms.

[0054] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R c and R d are different and each independently represent a hydrogen atom, C 1-6 In some embodiments, R c and R d are different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R c is a hydrogen atom, and R dis C 1-6 is an alkyl group, and in some embodiments, R c is a hydrogen atom, and R d is CH3, In some embodiments, R c and R d are different and each independently selected from a hydrogen atom, CH and a deuterated methyl group; in some embodiments, R c and R d are different and each independently represent a hydrogen atom or CH3.

[0055] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R c is C 1-6 is an alkyl group, and R d is a hydrogen atom, and in some embodiments, R c is CH3 and R d is a hydrogen atom, and in some embodiments, R c is a 3- to 10-membered cycloalkyl group (preferably a cyclopropyl group), and R d is a hydrogen atom, and in some embodiments, R c is a hydrogen atom, and R d is a 3- to 10-membered cycloalkyl group (preferably a cyclopropyl group).

[0056] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 alkyl group and / or R b Halo C 1-6 alkyl group and / or Rc is a hydrogen atom, and / or R d is C 1-6 is an alkyl group, and in some embodiments, R a is CH3, and / or R b is CF3, and / or R c is a hydrogen atom, and / or R d is CH3.

[0057] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), or (VIII) or a pharmaceutically acceptable salt thereof, wherein X is O.

[0058] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R' is a hydrogen atom or C 1-6 It is an alkyl group, and preferably R' is a hydrogen atom.

[0059] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein X is O and / or R' is a hydrogen atom.

[0060] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III) or (III-1) or a pharmaceutically acceptable salt thereof, wherein ring A is a 6-membered heteroaryl group, preferably ring A is selected from a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group and a triazinyl group, more preferably ring A is a pyridinyl group or a pyrimidinyl group, and more preferably ring A is [ka] and most preferably [ka] wherein the * end is linked to -NR', [ka] Ends with R A is connected to

[0061] In some embodiments, Ring A is selected from a phenyl group, a pyridyl group, and a pyrimidinyl group; in some embodiments, Ring A is [ka] In some embodiments, ring A is selected from: [ka] In some embodiments, ring A is selected from: [ka] In some embodiments, ring A is selected from: [ka] In some embodiments, ring A is selected from [ka] In some embodiments, ring A is [ka] wherein the * end is linked to -NR', [ka] Ends with R A and in some embodiments, ring A is [ka] and the * terminus is linked to -NR'; [ka] Ends with one R A is linked to.

[0062] In some embodiments of the present disclosure, a compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is provided, [ka] teeth [ka] Selected from R A and r are as defined in general formula (I), preferably [ka] teeth [ka] Selected from R A and r are as defined in general formula (I), more preferably [ka] teeth [ka] Selected from R A is as defined in general formula (I), more preferably [ka] teeth [ka] and R A is as defined in general formula (I), most preferably [ka] teeth [ka] and R A is as defined in general formula (I).

[0063] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV) or a pharmaceutically acceptable salt thereof, wherein R A is C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -NR 3 R 4 , -C 1-6 Alkylene-NR 3 R 4 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 10-membered cycloalkyl group, the 3- to 10-membered heterocyclyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH C 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 R is selected from the group consisting of a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; 3 , R 4 , R 5 and R 6 is as defined in general formula (I), and in some embodiments, R A is an amino group, [ka] Selected from In some embodiments, R A is F, Cl, amino group, cyano group, [ka] Selected from In some embodiments, R A is F, Cl, amino group, cyano group, [ka] Selected from In some embodiments, R A is F, Cl, amino group, [ka] Selected from In some embodiments, R A is an amino group, [ka] Selected from In some embodiments, R A is an amino group, [ka] Selected from In some embodiments, R A teeth, [ka] Selected from In some embodiments, R A teeth, [ka] Selected from In some embodiments, R A teeth, [ka] In some embodiments, R A teeth, [ka] Selected from In some embodiments, R A teeth, [ka] Selected from In some embodiments, R A teeth, [ka] Selected from In some embodiments, R A teeth, [ka] In some embodiments, R A teeth, [ka] In some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and In some embodiments, R A teeth, [ka] In some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and in some embodiments, R A teeth [ka] and In some embodiments, R A is -C(O)NR 5 -OR 6 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 and -C(O)-C(O)-NR 3 R 4 wherein the alkylene is optionally selected from one or more R 01 Cy, R 3 , R 4 , R 5 , R 6 and R 01 is as defined in general formula (I), and in some embodiments, R A is -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(O)NR 5 -O-Alkylene-cycloalkyl group, -C(=NR 5 )NR 3 R 4 and -C(O)-C(O)-NR 3 R 4 wherein the alkylene and cycloalkyl groups are optionally selected from one or more R 01 Cy, R 3 , R 4 , R 5 , R 6 and R 01 is as defined in general formula (I), and in some embodiments, R A is -C(O)NR 5 -NR 3 R4 or -C(=NR 5 )NR 3 -OR 6 and R 3 , R 4 , R 5 and R 6 is as defined in general formula (I), and in some embodiments, R A is -C(O)NR 5 -NR 3 R 4 and R 3 , R 4 and R 5 is as defined in general formula (I), and in some embodiments, R A is -C(=NR 5 )NR 3 -OR 6 and R 3 , R 5 and R 6 is as defined in general formula (I), and in some embodiments, R A is -C(=NR 5 )NR 3 R 4 and R 3 , R 4 and R 5 is as defined in general formula (I), and in some embodiments, R A is -C(=NR 5 )NR 3 R 4 and R 3 , R 4 and R 5 are the same or different and each independently represent a hydrogen atom, C 1-6 selected from alkyl groups and 3- to 6-membered cycloalkyl groups, In some embodiments, R A is -C(O)-C(O)-NR 3 R 4 and R 3 and R 4 is as defined in general formula (I), and in some embodiments, R A is -C(O)-C(O)-NR 3 R 4 and R 3 and R 4are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, In some embodiments, R A is -C(O)NR 5 -NR 3 R 4 or -C(=NR 5 )NR 3 -OR 6 and R 3 , R 4 , R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 It is an alkyl group.

[0064] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II') or (II-1) or a pharmaceutically acceptable salt thereof, wherein R A is an amino group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene -NH2, -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , a 3- to 8-membered cycloalkyl group and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 8-membered cycloalkyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH C 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6R is selected from the group consisting of a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; 3 , R 4 , R 5 and R 6 is as defined in general formula (I), In some embodiments, R A is an amino group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene -NH2, -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , a 3- to 6-membered cycloalkyl group and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 6-membered cycloalkyl group, and the 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, an amino group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, R 3 , R 4 , R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, In some embodiments, R A is an amino group, C 1-6 hydroxyalkyl groups, [ka] Among them, G 1 is a nitrogen atom or CR G and G 2 is a nitrogen atom or CR G and R A4 is a hydrogen atom, a hydroxyl group, C 1-6 Alkyl groups and C 1-6 is a hydroxyalkyl group, and R 3, R 4 , R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and R 01 are independently a hydroxy group, a cyano group, an amino group, and C 1-6 hydroxyalkyl groups, and each R G and R N are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, t is selected from 0, 1, 2 and 3, u1 is selected from 0, 1, 2 and 3, u2 is selected from 0, 1, 2 and 3, and u3 is selected from 1, 2 and 3; In some embodiments, R A is an amino group, [ka] In some embodiments, R A teeth, [ka] Selected from In some embodiments, R A is C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene-NH2, -C(O)NR 5 -OR 6 , a 3- to 6-membered cycloalkyl group and a 5- or 6-membered heteroaryl group, 1-6 The alkylene group, the 3- to 6-membered cycloalkyl group, and the 5- or 6-membered heteroaryl group may optionally be one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R A Ha-C1-6 Alkylene -NH2 or -C(O)NR 5 -OR 6 and the above C 1-6 The alkylene group may optionally be one or more R 01 is replaced by R 01 are each independently a hydroxy group and C 1-6 hydroxyalkyl groups, R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R A teeth, [ka] Selected from In some embodiments, R A is a 3- to 6-membered cycloalkyl group or a 5- or 6-membered heteroaryl group, and the 3- to 6-membered cycloalkyl group and the 5- or 6-membered heteroaryl group each independently optionally contain one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, an amino group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, and in some embodiments, R A is a 3- to 6-membered cycloalkyl group or a 5-membered heteroaryl group, and the 3- to 6-membered cycloalkyl group and the 5-membered heteroaryl group each independently and optionally contain one or more R 01 is replaced by R 01 are each independently a hydroxy group, a cyano group, an amino group, or C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, and in some embodiments, R A teeth, [ka] Selected from G 1 is a nitrogen atom or CR G and G 2 is a nitrogen atom or CR G and R01 is a hydroxy group, a cyano group, an amino group and C 1-6 hydroxyalkyl groups, and each R G and R N are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and u3 is 1 or 2; In some embodiments, each R A are the same or different and each independently represent a fluorine atom, a chlorine atom, a hydroxy group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -NR 3 R 4 , -C 1-6 Alkylene-NR 3 R 4 , -OC 1-6 Alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(=NR 5 )(O)R 6 , a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, a 5- to 14-membered heteroaryl group, -OC 1-6 Alkylene-5~14 heteroaryl group and -OC 1-6 alkylene-3 to 10-membered heterocyclyl groups, among which the above C 1-6 The alkylene group, the 3- to 10-membered cycloalkyl group, the 3- to 10-membered heterocyclyl group, the 6- to 10-membered aryl group, and the 5- to 14-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, or -NHC 1-6Alkyl group, -N(C 1-6 alkyl)2, acetyl group, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 R is selected from the group consisting of a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; 3 , R 4 , R 5 , R 6 and v are as defined in general formula (I), In some embodiments, R A are the same or different and each independently represent a hydroxy group, an amino group, -C 1-6 Alkylene-NH2, -OC 1-6 Alkylene-NH2, C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, 3- to 8-membered cycloalkyl group, 4- to 7-membered heterocyclyl group, phenyl group, 5- or 6-membered heteroaryl group and -OC 1-6 alkylene-5 or 6-membered heteroaryl groups, among which the above C 1-6 The alkylene group, the 3- to 8-membered cycloalkyl group, the 4- to 7-membered heterocyclyl group, the phenyl group, and the 5- or 6-membered heteroaryl group each independently optionally may be one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, or -NHC 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; In some embodiments, R A are the same or different and each independently represent an amino group, C 1-6 Hydroxyalkyl group, C 1-6 hydroxyalkoxy group, phenyl group, and 5- or 6-membered heteroaryl group, each of which is independently optionally selected from one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, or -NHC 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 In some embodiments, R is selected from hydroxyalkyl groups, 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 6- to 10-membered aryl groups, and 5- to 14-membered heteroaryl groups. A are the same or different and each independently represent an amino group, [ka] In some embodiments, R A teeth [ka] is.

[0065] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is [ka] teeth [ka] and each R B are the same or different and are each independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, and heterocyclyl groups, and the alkyl, alkoxy, cycloalkyl, and heterocyclyl groups are each independently optionally substituted with one or more groups selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, and heterocyclyl groups; p is 0, 1, 2, 3, or 4; and the rings A and R A is as defined in general formula (I), Preferably, [ka] teeth [ka] and R B is a halogen, hydroxyl group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl and Halo C 1-6 alkoxy groups, p is selected from 0, 1 and 2, and ring A is a phenyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, or [ka] Selected from R A is as defined in general formula (I), more preferably [ka] teeth [ka] and R B is a halogen, hydroxyl group, C 1-6 Alkyl and Halo C 1-6alkyl group, p is 0 or 1, ring A is selected from phenyl group, pyridinyl group and pyrimidinyl group, R A is an amino group, C 1-6 Hydroxyalkyl group, C 1-6 hydroxyalkoxy group, phenyl group, and 5- or 6-membered heteroaryl group, each of which is independently optionally selected from one or more R 01 is replaced by R 01 is as defined in general formula (I).

[0066] In some embodiments of the present disclosure, each R B are the same or different and each independently a halogen; in some embodiments, R B is F.

[0067] In some embodiments of the present disclosure, each R B are the same or different and each independently represent a halogen, C 1-6 Alkyl groups and C 1-6 and / or p is 0 or 1; in some embodiments, each R B are the same or different and each independently represent a halogen; and / or p is 0 or 1.

[0068] In some embodiments of the present disclosure, p is 0 or 1; in some embodiments, p is 0; and in some embodiments, p is 1.

[0069] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is [ka] teeth [ka] and R 1A , R 2A and R 3Aare the same or different and each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, a hydroxy group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -NR 3 R 4 , -C 1-6 Alkylene-NR 3 R 4 , -OC 1-6 Alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4 , -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, a 5- to 14-membered heteroaryl group, -OC 1-6 Alkylene-5~14 heteroaryl group and -OC 1-6 alkylene-3 to 10-membered heterocyclyl groups, among which the above C 1-6 The alkylene group, the 3- to 10-membered cycloalkyl group, the 3- to 10-membered heterocyclyl group, the 6- to 10-membered aryl group, and the 5- to 14-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 , R 3 , R 4 , R 5 , R 6 and v are as defined in general formula (I).

[0070] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), or (II-1) or a pharmaceutically acceptable salt thereof, wherein R Ais a halogen, hydroxyl group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl and Halo C 1-6 The alkoxy group is selected from the group consisting of alkoxy groups.

[0071] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II') or (II-1) or a pharmaceutically acceptable salt thereof, wherein r-1 is 0, 1 or 2, in some embodiments r-1 is 0, and in some embodiments r-1 is 1.

[0072] In some embodiments of the present disclosure, the compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof is [ka] teeth [ka] and R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an amino group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl groups and C 1-6 hydroxyalkoxy groups, R 3A is a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkenyl group, -NR 3 R 4 , -Alkylene-NR 3 R 4 , -O-alkylene-NR 3 R 4 , -C(=NR 5 )R 6 , -S(O) v NR 3 R 4, -NR 5 S(O) v R 6 , -S(O) v R 6 , -S(=NR 5 )(O)R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)NR 3 R 4 , -C(O)NR 5 -OR 6 , -P(O)R 7 R 8 , -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 , -C(O)-C(O)-NR 3 R 4 , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, an -O-alkylene-heteroaryl group, and an -O-alkylene-heterocyclyl group, wherein the alkenyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, and heteroaryl group each independently optionally may be selected from the group consisting of one or more R 01 is replaced by R 01 , R 3 , R 4 , R 5 , R 6 and v are as defined in general formula (I), In some embodiments, R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an amino group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl groups and C 1-6hydroxyalkoxy groups, R 3A is a hydroxy group, an amino group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene-NH2, -OC 1-6 Alkylene -NH2, phenyl group, 5- or 6-membered heteroaryl group and -OC 1-6 alkylene-5 or 6-membered heteroaryl groups, 1-6 The alkylene group, phenyl group and 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH C 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group; Preferably, R 1A and R 2A are the same or different and each independently represent a hydrogen atom, a halogen, or C 1-6 Alkyl and Halo C 1-6 alkyl groups, R 3A is a hydroxy group, an amino group, C 1-6 Alkoxy group, C 1-6 Hydroxyalkyl group, C 1-6 Hydroxyalkoxy group, -C 1-6 Alkylene-NH2, -OC 1-6 Alkylene -NH2, phenyl group, 5- or 6-membered heteroaryl group and -OC 1-6 alkylene-5 or 6-membered heteroaryl groups, 1-6The alkylene group, phenyl group and 5- or 6-membered heteroaryl group each independently optionally include one or more R 01 is replaced by R 01 each independently represents a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, -NH C 1-6 Alkyl group, -N(C 1-6 Alkyl)2, C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, C 1-6 It is selected from a hydroxyalkyl group, a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocyclyl group, a 6- to 10-membered aryl group, and a 5- to 14-membered heteroaryl group.

[0073] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II) or (IV) or a pharmaceutically acceptable salt thereof, wherein R 3A is F, Cl, amino group, [ka] Selected from In some embodiments, R 3A is an amino group, [ka] Selected from In some embodiments, R 3A is an amino group, [ka] Selected from In some embodiments, R 3A teeth, [ka] Selected from In some embodiments, R 3A teeth, [ka] Selected from In some embodiments, R 3A teeth, [ka] Selected from In some embodiments, R 3A teeth, [ka] Selected from In some embodiments, R 3A teeth, [ka] Selected from In some embodiments, R 3A teeth, [ka] In some embodiments, R 3A teeth [ka] and in some embodiments, R 3A teeth [ka] and in some embodiments, R 3A teeth [ka] and in some embodiments, R 3A teeth [ka] and In some embodiments, R 3A is -C(O)NR 5 -OR 6, -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(=NR 5 )NR 3 R 4 and -C(O)-C(O)-NR 3 R 4 wherein the alkylene group is optionally selected from one or more R 01 Cy, R 3 , R 4 , R 5 , R 6 and R 01 is as defined in general formula (I), and in some embodiments, R 3A is -C(O)NR 5 -NR 3 R 4 , -C(=NR 5 )NR 5 -OR 6 , -C(O)NR 5 -Alkylene-Cy, -C(O)NR 5 -O-Alkylene-cycloalkyl group, -C(=NR 5 )NR 3 R 4 and -C(O)-C(O)-NR 3 R 4 wherein the alkylene group is optionally selected from one or more R 01 Cy, R 3 , R 4 , R 5 , R 6 and R 01 is as defined in general formula (I), and in some embodiments, R 3A is -C(O)NR 5 -NR 3 R 4 or -C(=NR 5 )NR 3 -OR 6 and R 3 , R 4 , R 5 and R 6is as defined in general formula (I), and in some embodiments, R 3A is -C(O)NR 5 -NR 3 R 4 and R 3 , R 4 and R 5 is as defined in general formula (I), and in some embodiments, R 3A is -C(=NR 5 )NR 3 -OR 6 and R 3 , R 5 and R 6 is as defined in general formula (I), In some embodiments, R 3A is -C(=NR 5 )NR 3 R 4 and R 3 , R 4 and R 5 is as defined in general formula (I), and in some embodiments, R 3A is -C(=NR 5 )NR 3 R 4 and R 3 , R 4 and R 5 are the same or different and each independently represent a hydrogen atom, C 1-6 selected from alkyl groups and 3- to 6-membered cycloalkyl groups, In some embodiments, R 3A is -C(O)-C(O)-NR 3 R 4 and R 3 and R 4 is as defined in general formula (I), and in some embodiments, R 3A is -C(O)-C(O)-NR 3 R 4 and R 3 and R 4 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, In some embodiments, R 3A is -C(O)NR 5 -NR3 R 4 or -C(=NR 5 )NR 3 -OR 6 and R 3 , R 4 , R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 It is an alkyl group.

[0074] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1) or (IV) or a pharmaceutically acceptable salt thereof, wherein Cy is a 3- to 6-membered cycloalkyl group, and the 3- to 6-membered cycloalkyl group optionally contains halogen, C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 In some embodiments, Cy is a cyclopropyl group, which is optionally substituted with one or more substituents selected from an alkoxy group, a hydroxy group, an amino group, a cyano group, and a 3- to 6-membered cycloalkyl group. In some embodiments, Cy is a cyclopropyl group, which is optionally substituted with one or more substituents selected from a halogen, a C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 and is substituted with one or more substituents selected from an alkoxy group, a hydroxy group, a cyano group, and a 3- to 6-membered cycloalkyl group. In some embodiments, Cy is [ka] In some embodiments, Cy is selected from cyclopropyl, cyclobutyl, and cyclopentyl groups, and the cyclopropyl, cyclobutyl, and cyclopentyl groups are optionally selected from halogen, C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 It is substituted with one or more substituents selected from an alkoxy group and a hydroxy group.

[0075] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are the same or different and each independently represent a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, preferably R 3 and R 4 are the same or different and each independently represent a hydrogen atom or C 1-6 alkyl group, more preferably R 3 and R 4 are both hydrogen atoms.

[0076] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 3 is a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Hydroxyalkyl groups, 3- to 6-membered cycloalkyl groups and 3- to 6-membered cycloalkyl groups 1-6 alkyl groups, and 1-6 The alkyl group and the 3- to 6-membered cycloalkyl group are each independently optionally substituted with a halogen, a hydroxy group, an oxo group, C 1-6 Alkyl groups and C 1-6 substituted with one or more selected from alkoxy groups, In some embodiments, R 3 is a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Hydroxyalkyl groups, 3- to 6-membered cycloalkyl groups and 3- to 6-membered cycloalkyl groups 1-6 alkyl groups, and in some embodiments, R3 is a hydrogen atom, C 1-6 In some embodiments, R 3 is selected from a hydrogen atom, a methyl group, an ethyl group, and a cyclopropyl group, and in some embodiments, R 3 is an ethyl group or a cyclopropyl group, In some embodiments, R 3 is a 3- to 6-membered cycloalkyl group, and in some embodiments, R 3 is a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R 3 is a hydrogen atom, C 1-6 Alkyl group, OR 23 , 3-6 membered cycloalkyl groups and C(O)OR 23 Selected from R 23 is as defined in general formula (I), and in some embodiments, R 3 is a hydrogen atom, C 1-6 Alkyl group, OR 23 , 3-6 membered cycloalkyl groups and C(O)OR 23 Selected from R 23 is a hydrogen atom or C 1-8 is an alkyl group, In some embodiments, R 3 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Alkoxy groups, 3-6 membered cycloalkyl groups and C(O)OR 23 Selected from R 23 is as defined in general formula (I), In some embodiments, R 3 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Alkoxy groups, 3-6 membered cycloalkyl groups and C(O)OR 23 Selected from R 23 is a hydrogen atom or C 1-8 is an alkyl group, In some embodiments, R 3 represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a cyclopropyl group, [ka] In some embodiments, R 3 represents a hydrogen atom, a methyl group, an ethyl group, a methoxy group, a cyclopropyl group, [ka] In some embodiments, R 3 represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, [ka] Selected from In some embodiments, R 3 is a hydrogen atom, and in some embodiments, R 3 is a methyl group, and in some embodiments, R 3 is an ethyl group, and in some embodiments, R 3 is a hydroxy group, and in some embodiments, R 3 is a methoxy group, and in some embodiments, R 3 is a cyclopropyl group, and in some embodiments, R 3 is C(O)OR 23 and R 23 is C 1-8 It is an alkyl group.

[0077] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 4 is a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R 4 is a hydrogen atom or a methyl group, and in some embodiments, R 4 is a hydrogen atom, and in some embodiments, R 4 is C 1-6is an alkyl group, and in some embodiments, R 4 is a methyl group or an ethyl group.

[0078] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 3 is a hydrogen atom, C 1-6 Alkyl group, OR 23 and C(O)OR 23 Selected from R 23 is as defined in general formula (I), and / or R 4 is a hydrogen atom, and in some embodiments, R 3 is a hydrogen atom, a hydroxyl group, C 1-6 Alkyl group, C 1-6 Alkoxy group, deuterated C 1-6 Alkoxy group, -O-3 to 6-membered cycloalkyl group and C(O)OR 23 Selected from R 23 is C 1-8 alkyl group and / or R 4 is a hydrogen atom, and in some embodiments, R 3 represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a cyclopropyl group, [ka] and / or R 4 is a hydrogen atom.

[0079] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 20 and R 21 are the same or different and each independently represent a hydrogen atom, C 1-8 Alkyl group, halo C1-8 Alkyl groups and C 1-8 hydroxyalkyl groups, and in some embodiments, R 20 and R 21 are the same or different and each independently represent a hydrogen atom or C 1-8 is an alkyl group, and in some embodiments, R 20 is a hydrogen atom, and R 21 is C 1-8 is an alkyl group, and in some embodiments, R 20 is a hydrogen atom, and R 21 is an n-hexyl group.

[0080] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 23 is a hydrogen atom, C 1-8 Alkyl groups, deuterated C 1-6 Alkyl group, halo C 1-8 Alkyl groups and C 1-8 hydroxyalkyl groups, and in some embodiments, R 23 is a hydrogen atom, C 1-8 Alkyl group, halo C 1-8 Alkyl groups and C 1-8 hydroxyalkyl groups, and in some embodiments, R 23 is a hydrogen atom, C 1-8 Alkyl groups and deuterated C 1-6 alkyl groups, and in some embodiments, R 23 is selected from a hydrogen atom, a methyl group, a deuterated methyl group, a cyclopropyl group, an isopropyl group, and an n-hexyl group; in some embodiments, R 23 is C 1-8 is an alkyl group, and in some embodiments, R 23 is a hydrogen atom or a methyl group, and in some embodiments, R 23 is selected from a hydrogen atom, a methyl group, and a deuterated methyl group, and in some embodiments, R 23is an isopropyl group or an n-hexyl group.

[0081] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 22 is a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R 22 is a hydrogen atom.

[0082] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 5 is a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, preferably R 5 is a hydrogen atom or C 1-6 is an alkyl group, and in some embodiments, R 5 is a hydrogen atom, In some embodiments, R 5 is a hydrogen atom, C 1-6 Alkyl group, OR 23 , 3-6 membered cycloalkyl groups and C(O)OR 23 Selected from R 23 is as defined in general formula (I), In some embodiments, R 5 is a hydrogen atom, a deuterium atom, C 1-6 Alkyl groups, deuterated C 1-6 Alkyl group, C 1-6 Alkoxy group, deuterated C 1-6 Alkoxy group, 3-6 membered cycloalkyl group, -O-3-6 membered cycloalkyl group and C(O)OR 23 Selected from R 23is a hydrogen atom or C 1-8 is an alkyl group, and in some embodiments, R 5 is a hydrogen atom, a hydroxyl group, C 1-6 Alkyl group, C 1-6 Alkoxy group, deuterated C 1-6 Alkoxy group, -O-3 to 6-membered cycloalkyl group and C(O)OR 23 Selected from R 23 is C 1-8 is an alkyl group, and in some embodiments, R 5 is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Alkoxy group, deuterated C 1-6 Alkoxy group, -O-3 to 6-membered cycloalkyl group and C(O)OR 23 Selected from R 23 is C 1-8 is an alkyl group, and in some embodiments, R 5 is a hydroxy group or C 1-6 is an alkoxy group, In some embodiments, R 5 represents a hydrogen atom, a deuterium atom, a methyl group, a deuterated methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, an -O-cyclopropyl group, [ka] In some embodiments, R 5 is a hydrogen atom, a methyl group, a hydroxyl group, a methoxy group, OCD3, [ka] In some embodiments, R 5 represents a hydrogen atom, a methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, an -O-cyclopropyl group, [ka] In some embodiments, R 5 is a hydroxy group or a methoxy group, In some embodiments, R5 is a methyl group, and in some embodiments, R 5 is a deuterated methyl group, and in some embodiments, R 5 is a hydroxy group, and in some embodiments, R 5 is a methoxy group, and in some embodiments, R 5 is a deuterated methoxy group, and in some embodiments, R 5 is OCD3, and in some embodiments, R 5 is a cyclopropyl group or an —O-cyclopropyl group, and in some embodiments, R 5 teeth [ka] and in some embodiments, R 5 is selected from a hydrogen atom, a methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, and an -O-cyclopropyl group; in some embodiments, R 5 is selected from a hydrogen atom, a methyl group, a hydroxy group and a methoxy group.

[0083] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (VI), (VII), (VI'), (VI'-1), or (VII') or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are both hydrogen atoms, and R 5 represents a hydrogen atom, a deuterium atom, a methyl group, a deuterated methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, an -O-cyclopropyl group, [ka] or R 5 is a hydrogen atom, and R 4 is a hydrogen atom, and R 3 represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, [ka] In some embodiments, R 3 and R 4 are both hydrogen atoms, and R 5 represents a hydrogen atom, a deuterium atom, a methyl group, a deuterated methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, an -O-cyclopropyl group, [ka] Selected from.

[0084] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (IV), (VI) or a pharmaceutically acceptable salt thereof, wherein R 3a and R 4 are both hydrogen atoms, and R 5 represents a hydrogen atom, a deuterium atom, a methyl group, a deuterated methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, an -O-cyclopropyl group, [ka] or R 5 is a hydrogen atom, and R 4 is a hydrogen atom, and R 3a represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, [ka] In some embodiments, R 3a and R 4 are both hydrogen atoms, and R 5 represents a hydrogen atom, a deuterium atom, a methyl group, a deuterated methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, an -O-cyclopropyl group, [ka] Selected from.

[0085] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 6 is a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, preferably R 6 is a hydrogen atom or C 1-6 alkyl group, more preferably R 6 is C 1-6 alkyl group, most preferably R 6 is CH3, In some embodiments, R 6 is a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkoxy group, C 1-6 Hydroxyalkyl groups, 3- to 6-membered cycloalkyl groups and 3- to 6-membered cycloalkyl groups 1-6 alkyl groups, and in some embodiments, R 6 is C 1-6 Alkyl groups, 3- to 6-membered cycloalkyl groups and 3- to 6-membered cycloalkyl groups 1-6 alkyl groups, and in some embodiments, R 6 is C 1-6 Alkyl group or 3- to 6-membered cycloalkyl group 1-6 is an alkyl group, and in some embodiments, R 6 is CH3 or [ka] and in some embodiments, R 6 is a hydrogen atom, In some embodiments, R 6 is a hydrogen atom, C 1-6 Alkyl groups, deuterated C 1-6In some embodiments, R 6 is selected from a hydrogen atom, a methyl group, a deuterated methyl group, and a cyclopropyl group, and in some embodiments, R 6 is selected from a hydrogen atom, a methyl group, and a deuterated methyl group, and in some embodiments, R 6 is a hydrogen atom or a methyl group.

[0086] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 7 and R 8 are the same or different and each independently represent a hydrogen atom, C 1-6 Alkyl group, halo C 1-6 Alkyl groups and C 1-6 hydroxyalkyl groups, preferably R 7 and R 8 are each independently a hydrogen atom or C 1-6 alkyl group, more preferably R 7 and R 8 are each independently C 1-6 alkyl group, most preferably R 7 and R 8 are both CH3, and in some embodiments, R 7 and R 8 are the same or different and each independently C 1-6 is an alkyl group or an amino group, and in some embodiments, R 7 and R 8 are the same or different and each independently represent a methyl group or an amino group; in some embodiments, R 7 is a methyl group, and R 8 is an amino group.

[0087] In some embodiments of the present disclosure, the compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 01 are each independently a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl)2 group, a C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkyl group, C 1-6 Haloalkoxy group, C 1-6 In some embodiments, R is selected from a hydroxyalkyl group, a 3- to 6-membered cycloalkyl group, and a 3- to 6-membered heterocyclyl group. 01 are each independently a halogen, a hydroxy group, a cyano group, an oxo group, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkyl groups and C 1-6 haloalkoxy groups, and in some embodiments, R 01 are each independently a halogen, a hydroxy group, an oxo group, or C 1-6 Alkyl groups and C 1-6 In some embodiments, R 01 is a deuterium atom.

[0088] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R X1 is a hydrogen atom, halogen, hydroxyl group, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6selected from an alkoxy group, a 3- to 6-membered cycloalkyl group, a 4- to 7-membered heterocyclyl group, a 3- to 6-membered cycloalkyloxy group, and a 4- to 7-membered heterocyclyloxy group, and the 3- to 6-membered cycloalkyl group, the 4- to 7-membered heterocyclyl group, the 3- to 6-membered cycloalkyloxy group, and the 4- to 7-membered heterocyclyloxy group each independently and optionally may be one or more R 03 is replaced by R 03 are each independently a halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, preferably R X1 is a hydroxy group, C 1-6 Alkoxy and HaloC 1-6 alkoxy groups, more preferably R X1 is C 1-6 is an alkoxy group, and most preferably R X1 is a methoxy group, In some embodiments, R X1 is a hydroxy group, C 1-6 In some embodiments, R X1 is a hydroxyl group, a methoxy group, and [ka] In some embodiments, R X1 is a hydroxy group, and in some embodiments, R X1 teeth [ka] and in some embodiments, R X1 is a hydroxy group, a methoxy group, a deuterated methoxy group, [ka] In some embodiments, R X1 is a hydroxy group, a methoxy group, OCD3 and [ka] In some embodiments, R X1 is a deuterated methoxy group, and in some embodiments, R X1 is OCD3.

[0089] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R X2 is a hydrogen atom, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 R is selected from an alkoxy group, a 3- to 6-membered cycloalkyl group, and a 4- to 7-membered heterocyclyl group, and is preferably X2 is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, more preferably R X2 is halogen, and most preferably R X2 is a fluorine atom.

[0090] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R X3 is a hydrogen atom, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 R is selected from an alkoxy group, a 3- to 6-membered cycloalkyl group, and a 4- to 7-membered heterocyclyl group, and is preferably X3 is a hydrogen atom, halogen, C 1-6 Alkyl and Halo C 1-6 alkyl groups, more preferably R X3 is halogen, and most preferably RX3 is a fluorine atom.

[0091] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R X1 , R X2 and R X3 are the same or different and each independently represent a hydrogen atom, a halogen, a hydroxyl group, or C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl group, halo C 1-6 In some embodiments, R X1 , R X2 and R X3 are the same or different and each independently represent a halogen, a hydroxyl group, C 1-6 In some embodiments, R X1 , R X2 and R X3 are the same or different and each independently represent F, a hydroxy group, a methoxy group, or [ka] Selected from.

[0092] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R X1 is a hydroxy group, C 1-6 selected from an alkoxy group and a 3- to 6-membered cycloalkyloxy group, and / or R X2 is a halogen, and / or RX3 is halogen, and in some embodiments, R X1 is a hydroxyl group, a methoxy group, and [ka] and / or R X2 is F and / or R X3 is F.

[0093] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, wherein R X4 and R X5 are each independently a hydrogen atom, a halogen, or C 1-6 Alkyl group, C 1-6 Alkoxy group, haloC 1-6 Alkyl and Halo C 1-6 alkoxy groups, preferably R X4 and R X5 are both hydrogen atoms.

[0094] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein R 7a and R 8a are the same or different and each independently represent a hydrogen atom, C 1-6 In some embodiments, R 7a and R 8a are the same or different and each independently represent a hydrogen atom or F.

[0095] In some embodiments of the present disclosure, the compound is represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein n is selected from 0, 1, 2 and 3, preferably n is 0 or 1, and more preferably n is 0.

[0096] In some embodiments of the present disclosure, the compound is represented by the above general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein s is selected from 0, 1, 2 and 3, preferably s is 0 or 1, more preferably s is 0.

[0097] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein r is selected from 0, 1 and 2, preferably r is 1, and in some embodiments, r is 2.

[0098] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (I), (II), (II'), (II-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or a pharmaceutically acceptable salt thereof, wherein v is 1 or 2, and preferably v is 2.

[0099] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, wherein R a and R b are different and independently C 1-6 Alkyl or halo C 1-6 is an alkyl group, and R c and R d are different and each independently represent a hydrogen atom or C1-6 is an alkyl group, X is O, and R' is a hydrogen atom or C 1-6 is an alkyl group, ring A is a pyridyl group or a pyrimidinyl group, and R A is an amino group, [ka] Selected from R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen and r is 1.

[0100] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and X is O; [ka] and R A is an amino group, [ka] and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0101] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II') or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6is an alkyl group, R' is a hydrogen atom, X is O, ring A is a pyridyl group or a pyrimidinyl group, r-1 is 0, and R 5 is a hydrogen atom, and R 3a is a hydrogen atom, C 1-6 Alkyl groups and C 1-6 alkoxy groups, R 4 is a hydrogen atom or a methyl group, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0102] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II-1) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, X is O, ring A is a pyridyl group or a pyrimidinyl group, r-1 is 0, and R 5 is a hydrogen atom, and R 3 is a hydrogen atom, C 1-6 R is selected from alkyl groups and 3- to 6-membered cycloalkyl groups; 4 is a hydrogen atom or a methyl group, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0103] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R 3A teeth, [ka] Selected from R X1 is a methoxy group, and R X2 is a fluorine atom, and R X3 is a fluorine atom.

[0104] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R 3A teeth, [ka] Selected from R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0105] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R 3A is -C(O)NR 5 -NR 3 R 4 or -C(=NR 5 )NR 3 -OR6 and R 3 , R 4 , R 5 and R 6 are the same or different and each independently represent a hydrogen atom or C 1-6 is an alkyl group, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0106] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R 3A is -C(=NR 5 )NR 3 R 4 and R 3 , R 4 and R 5 are the same or different and each independently represent a hydrogen atom, C 1-6 R is selected from alkyl groups and 3- to 6-membered cycloalkyl groups; X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0107] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R1A and R 2A are both hydrogen atoms, and R 3A teeth, [ka] Selected from R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0108] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R 5 is a hydrogen atom, and R 3a is a hydrogen atom, C 1-6 Alkyl groups and C 1-6 alkoxy groups, R 4 is a hydrogen atom or a methyl group, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0109] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VII) or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R5 is a hydrogen atom, and R 3 is a hydrogen atom, C 1-6 R is selected from alkyl groups and 3- to 6-membered cycloalkyl groups; 4 is a hydrogen atom or a methyl group, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen.

[0110] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and R c is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen and R 1A and R 2A are both hydrogen atoms, and Q is CR 5A , N and N + -O - Selected from R 5A is a halogen and R 3 represents a hydrogen atom, a methyl group, an ethyl group, a methoxy group, a cyclopropyl group, [ka] Selected from R 4 is a hydrogen atom or a methyl group, and R 5 is a hydrogen atom.

[0111] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VIII) or a pharmaceutically acceptable salt thereof, wherein X is O and R a is C 1-6 is an alkyl group, and R b Halo C 1-6 is an alkyl group, and Rc is a hydrogen atom, and R d is C 1-6 is an alkyl group, R' is a hydrogen atom, and R X1 is C 1-6 is an alkoxy group, and R X2 is a halogen and R X3 is a halogen and R 1A and R 2A are both hydrogen atoms, and Q is CR 5A , N and N + -O - Selected from R 5A is a halogen and R 3 represents a hydrogen atom, a methyl group, an ethyl group, a methoxy group, a cyclopropyl group, [ka] Selected from R 4 is a hydrogen atom or a methyl group.

[0112] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxyl group, a methoxy group, and [ka] Selected from R X2 is F and R X3 is F, X is O, and R' is a hydrogen atom; [ka] teeth [ka] and each R B are the same or different and each independently represent a halogen; p is 0 or 1; and ring A is [ka] wherein the * end is linked to -NR'; [ka] Ends with R A is connected to

[0113] R A is F, Cl, amino group, cyano group, [ka] Selected from.

[0114] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxy group, a methoxy group, a deuterated methoxy group, [ka] Selected from R X2 is F and R X3 is F, X is O, and R' is a hydrogen atom; [ka] teeth [ka] and R B is F, p is 0 or 1, and ring A is [ka] wherein the * end is linked to -NR', [ka] Ends with R Ais connected to R A teeth, [ka] Selected from.

[0115] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxyl group, a methoxy group, and [ka] Selected from R X2 is F and R X3 is F, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and Q is CR 5A , N and N + -O - Selected from R 5A is a halogen and R 3 represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a cyclopropyl group, [ka] Selected from R 4 is a hydrogen atom or a methyl group, and R 5 is a hydrogen atom.

[0116] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxy group, a methoxy group, a deuterated methoxy group, [ka] Selected from R X2 is F and R X3 is F, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and Q is N or CR 5A and R 5A is F and R 3 is a hydrogen atom, and R 4 is a hydrogen atom, and R 5 represents a hydrogen atom, a deuterium atom, a methyl group, a deuterated methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, a cyclopropyl group, an -O-cyclopropyl group, [ka] Selected from.

[0117] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxyl group, a methoxy group, and [ka] Selected from R X2 is F and R X3 is F, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and Q is CR 5A , N and N + -O - Selected from R 5A is F and R 3 is a hydrogen atom, and R 4 is a hydrogen atom, and R 5 represents a hydrogen atom, a methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, an -O-cyclopropyl group, [ka] Selected from.

[0118] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxyl group, a methoxy group, and [ka] Selected from R X2 is F and R X3 is F, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R 3A teeth [ka] is.

[0119] In some embodiments of the present disclosure, there is provided a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, wherein R a is CH3 and R b is CF3 and R c is a hydrogen atom, and R d is CH3 and R X1 is a hydroxyl group, a methoxy group, and [ka] Selected from R X2 is F and R X3 is F, R' is a hydrogen atom, and R 1A and R 2A are both hydrogen atoms, and R A teeth [ka] is.

[0120] [Table 1-1]

Table 1-2

Table 1-3

Table 1-4

Table 1-5

Table 1-6

Table 1-7

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

Table 1-31

Table 1-32

Table 1-33

Table 1-34

Table 1-35

[0121] Another aspect of the present disclosure relates to a compound represented by general formula (IIA') or a salt thereof: [ka] Among them, ring A and R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 and r-1 are as defined in general formula (II').

[0122] Another aspect of the present disclosure relates to a compound represented by general formula (IIa') or a salt thereof: [ka] wherein R* is selected from a hydroxy group, an alkoxy group, and a halogen; Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 and r-1 are as defined in general formula (II').

[0123] Another aspect of the present disclosure relates to a compound represented by general formula (IIIA) or a salt thereof: [ka] Among them, t is chosen from 0, 1, 2, 3 and 4, R 12 and R 13 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group and a phenyl group, and preferably, R 12 and R 13 are the same or different and each independently represent a hydrogen atom, C1-6 alkyl groups and 5- or 6-membered cycloalkyl groups, most preferably R 12 and R 13 are both CH3, Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 and R X3 is as defined in general formula (III).

[0124] Another aspect of the present disclosure relates to a compound represented by general formula (IIIA-1) or a salt thereof: [ka] Among them, t is chosen from 0, 1, 2, 3 and 4, R 12 and R 13 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group and a phenyl group, and preferably, R 12 and R 13 are the same or different and each independently represent a hydrogen atom, C 1-6 alkyl groups and 5- or 6-membered cycloalkyl groups, most preferably R 12 and R 13 are both CH3, Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 and R X3 is as defined in general formula (III-1).

[0125] Another aspect of the present disclosure relates to a compound represented by general formula (IVA') or a salt thereof: [ka] Among them, R 1A , R 2A , R', R a , R b , Rc , R d , R X1 , R X2 and R X3 is as defined in general formula (IV).

[0126] Another aspect of the present disclosure relates to a compound represented by general formula (IVa') or a salt thereof: [ka] wherein R* is selected from a hydroxy group, an alkoxy group, and a halogen; R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 and R X3 is as defined in general formula (IV).

[0127] Another aspect of the present disclosure relates to a compound represented by general formula (VI'A) or a salt thereof: [ka] Among them, Q and R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 and R X3 is as defined in general formula (VI').

[0128] Another aspect of the present disclosure relates to a compound represented by general formula (VII'A) or a salt thereof: [ka] wherein R* is selected from a hydroxy group, an alkoxy group, and a halogen; Q, R 1A , R 2A , R', R a , R b, R c , R d , R X1 , R X2 and R X3 is as defined in general formula (VII').

[0129] Another aspect of the present disclosure relates to a compound represented by general formula (VIIIA) or a salt thereof: [ka] Among them, R L is selected from halogen, hydroxyl and alkoxy groups; Q, R 1A , R 2A , R', X, R a , R b , R c , R d , R X1 , R X2 and R X3 is as defined in general formula (VIII).

[0130] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11]

[0131] Another aspect of the present disclosure relates to a method for preparing a compound of general formula (I) above or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (Ia) or a salt thereof to a condensation reaction with a compound represented by general formula (Ib) or a salt thereof to obtain a compound represented by general formula (I) or a medicamentable salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, Ring A, R A , R', R a , R b , R c , R d , R e , X, X 1 , X 2 , X 3 , X 4 , X 5 and r are as defined in general formula (I).

[0132] Another aspect of the present disclosure relates to a method for preparing a compound of general formula (I) above or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IA') or a salt thereof with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (I) or a medicamentable salt thereof, wherein At least one R in general formula (I) A is -C(=NH)NR 5 -OR 6 or -C(=NH)NR3 R 4 and r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; Remaining R A are as defined in general formula (I), and ring A, R', R a , R b , R c , R d , R e , X, X 1 , X 2 , X 3 , X 4 , X 5 , R 3 , R 4 , R 5 and R 6 is as defined in general formula (I).

[0133] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof to a condensation reaction with a compound represented by general formula (Ib) or a salt thereof to obtain a compound represented by general formula (II) or a medicament-use salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, Ring A, R A , R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 and r are as defined in general formula (II).

[0134] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IIA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, At least one R in general formula (II) A is -C(=NR 5 )NR 3 R 4 and r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; R 3 and R 4 are all hydrogen atoms, and the remaining R A is as defined in general formula (II), Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 and R 5 is as defined in general formula (II).

[0135] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IIA') or a salt thereof with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II) or a medicamentable salt thereof, wherein At least one R in general formula (II) A is -C(=NH)NR 5 -OR 6 or -C(=NH)NR 3 R 4 and r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; Remaining R A is as defined in general formula (II), Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and R 6 is as defined in general formula (II).

[0136] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IIa') or a salt thereof with an amine or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II) or a medicament-use salt thereof, wherein: The above amines are 5 -OR 6 , HNR 5 -NR 3 R 4 and HNR 5 -alkylene-Cy; R* is selected from a hydroxy group, an alkoxy group, and a halogen; At least one R in general formula (II) A is -C(O)NR 5 -OR 6 , -C(O)NR 5 -NR 3 R 4 and -C(O)NR 5 -alkylene-Cy, and the remaining R A is as defined in general formula (II), r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; Ring A, R', X, R a , R b , Rc , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 , R 6 and Cy are as defined in general formula (II).

[0137] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IIA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II') or a pharmaceutically acceptable salt thereof, R 3a and R 4 are both hydrogen atoms, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 5 and r-1 are as defined in general formula (II').

[0138] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IIA') or a salt thereof with a compound represented by general formula (II'B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II') or a medicamentable salt thereof, wherein R 5 is a hydrogen atom, Ring A, R A , R', X, R a, R b , R c , R d , R X1 , R X2 , R X3 , R 3a , R 4 and r-1 are as defined in general formula (II').

[0139] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof to a condensation reaction with a compound represented by general formula (II'b) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II') or a medicamentable salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3a , R 4 , R 5 and r-1 are as defined in general formula (II').

[0140] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IIa') or a salt thereof with a compound represented by general formula (II-1B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II-1) or a medicamentable salt thereof, wherein: R* is selected from a hydroxy group, an alkoxy group, and a halogen; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and r-1 are as defined in general formula (II-1).

[0141] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof to a condensation reaction with a compound represented by general formula (II-1b) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II-1) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and r-1 are as defined in general formula (II-1).

[0142] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises hydrolyzing a compound represented by general formula (IIIA) or a salt thereof to obtain a compound represented by general formula (III) or a medicament-use salt thereof, wherein: R 12 and R 13 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group and a phenyl group, and preferably, R 12 and R 13 are the same or different and each independently represent a hydrogen atom, C 1-6 alkyl groups and 5- or 6-membered cycloalkyl groups, most preferably R 12 and R 13 are both CH3, Ring A, R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 and t are as defined in general formula (III).

[0143] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (III-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises hydrolyzing a compound represented by general formula (IIIA-1) or a salt thereof to obtain a compound represented by general formula (III-1) or a medicament-use salt thereof, wherein: R 12 and R 13 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group and a phenyl group, and preferably, R 12 and R 13 are the same or different and each independently represent a hydrogen atom, C 1-6 alkyl groups and 5- or 6-membered cycloalkyl groups, most preferably R 12 and R 13 are both CH3, Ring A, R', X, R a , R b , R c, R d , R X1 , R X2 , R X3 and t are as defined in general formula (III-1).

[0144] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (IVb) or a salt thereof to obtain a compound represented by general formula (IV) or a medicament-use salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A and R 3A is as defined in general formula (IV).

[0145] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IVA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, R 3A is -C(=NR 5 )NR 3 R 4 and R 3 and R 4 are both hydrogen atoms, R 1A , R2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 and R 5 is as defined in general formula (IV).

[0146] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IVA') or a salt thereof with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (IV) or a medicamentable salt thereof, wherein R 3A is -C(=NH)NR 5 -OR 6 or -C(=NH)NR 3 R 4 and R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and R 6 is as defined in general formula (IV).

[0147] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IVa') or a salt thereof with an amine or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (IV) or a medicamentable salt thereof, wherein: The above amines are 5 -OR 6 , HNR 5 -NR 3 R 4 and HNR 5 -alkylene-Cy; R* is selected from a hydroxy group, an alkoxy group, and a halogen; R 3A is -C(O)NR 5 -OR 6 , -C(O)NR 5 -NR 3 R 4 and -C(O)NR 5 -alkylene-Cy; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 , R 6 and Cy are as defined in general formula (IV).

[0148] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (V) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (Vb) or a salt thereof to obtain a compound represented by general formula (V) or a medicamentable salt thereof, wherein: R W1is a hydrogen atom or an amino-protecting group (preferably a tert-butylsulfinyl group), and R W2 is a hydrogen atom or a hydroxy protecting group (preferably TBS), R W1 is an amino protecting group, and / or R W2 is a hydroxy protecting group, the preparation method further comprises removing the protecting group; R 10 is a halogen (preferably a chlorine atom) or OH, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V).

[0149] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (V-1b) or a salt thereof are subjected to a condensation reaction to obtain a compound represented by general formula (V-1) or a medicinal salt thereof, or The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (V-2b) or a salt thereof to obtain a compound represented by general formula (V-2) or a medicinal salt thereof, wherein R W1 is a hydrogen atom or an amino-protecting group (preferably a tert-butylsulfinyl group), and R W2 is a hydrogen atom or a hydroxy protecting group (preferably TBS), R W1 is an amino protecting group, and / or R W2 is a hydroxy protecting group, the preparation method further comprises removing the protecting group; R 10 is a halogen (preferably a chlorine atom) or OH, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V-1).

[0150] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (V-1A) or a salt thereof is subjected to a deprotection reaction to obtain a compound represented by general formula (V-1) or a medicament-use salt thereof; The method comprises deprotecting a compound represented by general formula (V-2A) or a salt thereof to obtain a compound represented by general formula (V-2) or a medicament-use salt thereof, wherein: R W1 is an amino protecting group, and the amino protecting group is preferably Boc; R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V-1).

[0151] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (VI'B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI') or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 , R 4 and R 5 is as defined in general formula (VI').

[0152] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (VI'A) or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI') or a pharmaceutically acceptable salt thereof, R 3 and R 4 are both hydrogen atoms, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q and R 5 is as defined in general formula (VI').

[0153] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (VI'A) or a salt thereof with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI') or a pharmaceutically acceptable salt thereof, wherein R 5 is a hydrogen atom, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R 4 is as defined in general formula (VI').

[0154] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (VI'-1B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI'-1) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 , R 5 and R C is as defined in general formula (VI'-1).

[0155] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (VI'A) or a salt thereof with a compound represented by general formula (VI-1B') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI'-1) or a pharmaceutically acceptable salt thereof, wherein R 5 is a hydrogen atom, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R C is as defined in general formula (VI'-1).

[0156] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (VI') or a salt thereof (preferably trifluoroacetate) with a compound represented by general formula (VI'-1b) or a salt thereof to obtain a compound represented by general formula (VI'-1) or a medicamentable salt thereof, wherein: R 4 is a hydrogen atom, R 10 is halogen (preferably chlorine) or OH, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3, R 5 and R C is as defined in general formula (VI'-1).

[0157] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IVA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, R 3a and R 4 are both hydrogen atoms, R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 and R 5 is as defined in general formula (VI).

[0158] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IVA') or a salt thereof with a compound represented by general formula (II'B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, wherein R 5 is a hydrogen atom, R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3, R 3a and R 4 is as defined in general formula (VI).

[0159] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (VIb) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , R 3a , R 4 and R 5 is as defined in general formula (VI).

[0160] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VII') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (VII'B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VII') or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, R', R a , R b , R c , R d , R X1 , R X2, R X3 , R 1A , R 2A , Q, R 3 , R 4 and R 5 is as defined in general formula (VII').

[0161] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VII') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (VII') or a salt thereof with a compound represented by general formula (II-1B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VII') or a medicamentable salt thereof, wherein R* is selected from a hydroxy group, an alkoxy group, and a halogen; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 , R 4 and R 5 is as defined in general formula (VII').

[0162] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IVa') or a salt thereof with a compound represented by general formula (II-1B) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VII) or a medicamentable salt thereof, R* is selected from a hydroxy group, an alkoxy group, and a halogen; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; Among them, R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 and R 5 is as defined in general formula (VII).

[0163] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (VIIb) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VII) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , R 3 , R 4 and R 5 is as defined in general formula (VII).

[0164] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VIII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises condensing a compound represented by general formula (IIa) or a salt thereof with a compound represented by general formula (VIIIB) or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VIII) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R 4 is as defined in general formula (VIII).

[0165] Another aspect of the present disclosure relates to a method for preparing a compound represented by the above general formula (VIII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (VIIIA) or a salt thereof to a urethane exchange reaction with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VIII) or a medicamentable salt thereof, wherein R L is an alkoxy group, R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R 4 is as defined in general formula (VIII).

[0166] In some embodiments of the present disclosure, there is provided a method for preparing a compound represented by the above general formula (VIII) or a pharmaceutically acceptable salt thereof, wherein R Lis C 1-6 It is an alkoxy group, preferably a methoxy group or an ethoxy group.

[0167] In some embodiments of the present disclosure, there is provided a method for preparing a compound represented by the above general formula (II), (II-1), (IV) or (VII) or a pharmaceutically acceptable salt thereof, wherein R* is a hydroxy group, C 1-6 In some embodiments, R* is selected from hydroxy, methoxy, ethoxy, and chlorine; in some embodiments, R* is a hydroxy group.

[0168] In some embodiments of the present disclosure, there is provided a method for preparing a compound represented by the above general formula (II), (II-1), (IV) or (VII) or a pharmaceutically acceptable salt thereof, wherein R 4 is a hydrogen atom, C 1-6 selected from alkyl groups and amino protecting groups, R 4 is an amino-protecting group, the method further comprises the step of removing the amino-protecting group after the amidation reaction.

[0169] Another aspect of the present disclosure relates to a method for preparing a compound of the above general formula (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII') or (VIII) or a pharmaceutically acceptable salt thereof, the method comprising the steps of: X1 is an alkoxy group or a cycloalkoxy group, a compound represented by the general formula (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII') or (VIII), or a pharmaceutically acceptable salt thereof, is subjected to a dealkylation or decycloalkylation reaction to form R X1is -OH.

[0170] A method for preparing a compound of the present disclosure represented by the above general formula (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII') or (VIII) or a pharmaceutically acceptable salt thereof, wherein R X1 is a methoxy group, a deuterated methoxy group, and [ka] In some embodiments, R X1 is a methoxy group or [ka] is.

[0171] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a compound of the general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A of the present disclosure or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0172] The present disclosure further relates to the use of a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicament salt thereof, or a pharmaceutical composition comprising same, in the preparation of a medicament for inhibiting a voltage-gated sodium channel, preferably wherein said voltage-gated sodium channel is Nav1.8.

[0173] The present disclosure further relates to the use of a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicament salt thereof, or a pharmaceutical composition comprising same, in the preparation of a medicament for treating and / or preventing a disease or condition mediated by a voltage-gated sodium channel, preferably wherein said voltage-gated sodium channel is Nav1.8.

[0174] The present disclosure further relates to the use of a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicament salt thereof, or a pharmaceutical composition comprising same, in the preparation of a medicament for treating and / or alleviating pain or pain-related disorders, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia, wherein said pain is preferably selected from chronic pain, acute pain, inflammatory pain, cancer pain, post-operative pain, neuropathic pain, musculoskeletal pain, primary pain, intestinal pain, and idiopathic pain, and said post-operative pain is preferably selected from bunionectomy pain, herniorrhaphy pain, and abdominoplasty pain.

[0175] The present disclosure further relates to a method of inhibiting a voltage-gated sodium channel, comprising administering to a patient in need thereof a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicamentable salt thereof, or a pharmaceutical composition comprising same, wherein preferably said voltage-gated sodium channel is Nav1.8.

[0176] The present disclosure further relates to a method for treating and / or preventing a disease or condition mediated by a voltage-gated sodium channel, comprising administering to a patient in need thereof a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicamentable salt thereof, or a pharmaceutical composition comprising same, wherein preferably said voltage-gated sodium channel is Nav1.8.

[0177] The present disclosure further relates to a method for treating and / or preventing pain and pain-related disorders, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia, comprising administering to a patient in need thereof a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicamentable salt thereof, or a pharmaceutical composition comprising same, wherein said pain is preferably selected from chronic pain, acute pain, inflammatory pain, cancer pain, post-operative pain, neuropathic pain, musculoskeletal pain, primary pain, intestinal pain, and idiopathic pain, and said post-operative pain is preferably selected from bunionectomy pain, herniorrhaphy pain, and abdominoplasty pain.

[0178] The present disclosure further relates to a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicament salt thereof, or a pharmaceutical composition comprising same, for use as a medicament, preferably for inhibiting voltage-gated sodium channel activity.

[0179] The present disclosure further relates to a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicamentable salt thereof, or a pharmaceutical composition comprising same, for inhibiting a voltage-gated sodium channel, preferably the voltage-gated sodium channel is Nav1.8.

[0180] The present disclosure further relates to a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same, for use as a voltage-gated sodium channel inhibitor.

[0181] The present disclosure further relates to a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicament salt thereof, or a pharmaceutical composition comprising same, for use as a medicament for treating and / or preventing a disease or condition mediated by voltage-gated sodium channels.

[0182] The present disclosure further relates to a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicamentable salt thereof, or a pharmaceutical composition comprising same, for treating and / or preventing a disease or condition mediated by a voltage-gated sodium channel, preferably, wherein said voltage-gated sodium channel is Nav1.8.

[0183] The present disclosure further relates to a compound of general formula (I), (II), (II'), (II-1), (III), (III-1), (IV), (V), (V-1), (V-2), (VI), (VII), (VI'), (VI'-1), (VII'), (VIII) or Table A or a medicamentable salt thereof, or a pharmaceutical composition comprising the same, for treating and / or preventing pain or pain-related disorders, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or cardiac arrhythmia, wherein the pain is preferably selected from chronic pain, acute pain, inflammatory pain, cancer pain, neuropathic pain, musculoskeletal pain, primary pain, intestinal pain and idiopathic pain, and the post-operative pain is preferably selected from bunionectomy pain, herniorrhaphy pain and abdominoplasty pain.

[0184] The diseases or conditions described in the present disclosure are those that are treated and / or prevented by inhibiting a voltage-gated sodium channel, preferably, said voltage-gated sodium channel is Nav1.8.

[0185] Preferably, the disease or condition mediated by voltage-gated sodium channels described in the present disclosure is pain and pain-related disorders, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia, and preferably, said pain is selected from chronic pain, acute pain, inflammatory pain, cancer pain, neuropathic pain, musculoskeletal pain, primary pain, intestinal pain and idiopathic pain.

[0186] The neuropathic pain referred to in the present disclosure is preferably selected from trigeminal neuralgia, post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuralgia, burn syndrome, post-amputation pain, post-spinal cord injury pain, phantom pain, painful neuroma, traumatic neuroma, Morton's neuroma, nerve compression injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica, nerve avulsion injury, brachial plexus avulsion injury, complex regional pain syndrome, medication-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia, primary small fiber neuropathy, primary sensory neuralgia and trigeminal autonomic headache, and preferably, the neuropathic pain is selected from post-herpetic neuralgia, small fiber neuralgia, diabetic neuralgia or idiopathic small fiber neuralgia.

[0187] The musculoskeletal pain according to the present disclosure is preferably selected from osteoarthritic pain, back pain, cold pain, heat pain and toothache.

[0188] Bowel pain according to the present disclosure is preferably selected from inflammatory bowel disease pain, Crohn's disease pain or interstitial cystitis pain.

[0189] Inflammatory pain according to the present disclosure is preferably selected from rheumatoid arthritis pain and vulvodynia.

[0190] Idiopathic pain according to this disclosure includes fibromyalgia.

[0191] Acute pain according to this disclosure includes acute post-operative pain.

[0192] Post-operative pain according to the present disclosure includes joint replacement pain, soft tissue surgery pain, bunionectomy pain, herniorrhaphy pain and abdominoplasty pain, preferably selected from bunionectomy pain, herniorrhaphy pain and abdominoplasty pain.

[0193] The disease or condition described in the present disclosure is selected from acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, common neuralgia, epilepsy, epileptic disorders, neurodegenerative diseases, psychosis, anxiety, depression, bipolar disorder, myotonia, cardiac arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritic pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, headache, neck pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, post-operative pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility.

[0194] The pain and pain-related disorders described in this disclosure include femoral cancer pain, non-malignant chronic bone pain, rheumatoid arthritis, osteoarthritis, spinal stenosis, neuropathic low back pain, myofascial pain syndrome, myofibromyalgia, temporomandibular joint pain, chronic visceral pain, abdominal pain, pancreatic pain, IBS pain, chronic and acute headache, migraine, tension headache, cluster headache, chronic and acute neuropathic pain, post-herpetic neuralgia, diabetic neuropathy, HIV-associated neuropathy, trigeminal neuralgia, Charcot-Marie-Tooth neuropathy, hereditary sensory neuropathy, peripheral nerve injury, painful neuroma, ectopic proximal and distal discharges, radiculopathy, chemotherapy-induced neuropathic pain, radiation therapy-induced neuropathic pain, and post-mastectomy pain. Pain, central pain, spinal cord injury pain, post-stroke pain, thalamic pain, complex regional pain syndrome, phantom pain, phantom limb pain, intractable pain, acute pain, acute post-operative pain, acute musculoskeletal pain, arthralgia, mechanical low back pain, neck pain, myotendinomyositis, injury pain, exercise pain, acute visceral pain, pyelonephritis, appendicitis, cholecystitis, ileus, hernia, chest pain, cardiac pain, pelvic pain, renal colic, acute labor pain, delivery pain, incisional labor pain, acute inflammatory pain, burn pain, traumatic pain, acute intermittent pain, endometriosis, acute shingles pain, sickle cell anemia, acute pancreatitis, breakthrough pain, oral pain, sinus pain, toothache, pain from multiple sclerosis (MS), pain from depression, pain from leprosy, Behcet's disease disease pain, painful obesity, phlebitis pain, Guillain-Barre pain, painful legs and moving toes syndrome, Haglund syndrome, erythromelalgia, Fabry's disease pain, bladder and genitourinary system diseases, urinary incontinence, pathological cough, overactive bladder, bladder pain syndrome, interstitial cystitis (IC), prostatitis, complex regional pain syndrome type I (CRPS), complex regional pain syndrome type II (CRPS), widespread pain, paroxysmal severe pain, pruritus, tinnitus or colic-induced pain.

[0195] The diseases or conditions described in this disclosure include acute pain, subacute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, nociceptive pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, epilepsy, epileptic diseases, neurodegenerative diseases, psychosis, anxiety, depression, bipolar disorder, myotonia, cardiac arrhythmias, movement disorders, neurodegenerative diseases, endocrine disorders, ataxia, central nervous system disorders such as multiple sclerosis and irritable bowel syndrome. Pathological pain, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, non-specific chronic back pain, head pain, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postoperative pain, cancer pain (chronic cancer pain and breakthrough cancer pain), stroke (e.g., post-stroke central neuropathic pain), cervical sprain-related disorders, fragility fractures, spinal fractures, ankylosing spondylitis, pemphigus , Raynaud's disease, scleroderma, systemic lupus erythematosus, epidermolysis bullosa, gout, juvenile idiopathic arthritis, polymyalgia rheumatica, pyoderma gangrenosum, chronic widespread pain, diffuse idiopathic skeletal hypertrophy, disc degeneration / protrusion pain, radiculopathy, facet joint syndrome, post-back surgery pain syndrome, burns, carpal tunnel syndrome, Paget's disease pain, spinal stenosis, discitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry disease, mastocytosis, neurofibromatosis, The active compound may be selected from ophthalmic neuropathic pain, sarcoidosis, spondylolysis, spondylolisthesis, chemotherapy-induced oral mucositis, Charcot neuropathic osteoarthropathy, temporomandibular joint disorder, joint replacement pain, non-cardiogenic chest pain, genital pain, renal colic, biliary tract disease, vascular leg ulcers, Parkinson's disease pain, Alzheimer's disease pain, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or gastrointestinal motility disorders. The active compound may be prepared into a form suitable for administration by any suitable route, and the composition of the present disclosure may be prepared using one or more pharmaceutically acceptable carriers by conventional methods. Thus, the active compound of the present disclosure may be prepared into dosage forms for oral administration, injection (e.g., intravenous, intramuscular, or subcutaneous), inhalation, or insufflation. The compounds of the present disclosure may be prepared into dosage forms such as, for example, tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injectable solutions, dispersible powders or granules, suppositories, tablets for external use, or syrups.

[0196] As a general guideline, the active compounds of the present disclosure are preferably in unit dose form or in a form that can be self-administered by a patient as a single dose. The unit dose of the compounds or compositions of the present disclosure may be expressed as a tablet, capsule, cachet, bottled drug solution, drug powder, granules, topical tablet, suppository, reconstituted powder, or liquid formulation. A suitable unit dose may be 0.1 to 1000 mg.

[0197] The pharmaceutical composition according to the present disclosure may contain one or more additives in addition to the active compound, and the additives may be selected from components such as fillers (diluents), binders, wetting agents, disintegrants, or excipients. The composition may contain 0.1 to 99% by weight of the active compound, depending on the method of administration.

[0198] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg to 1000 mg.

[0199] In one embodiment, the pharmaceutical composition contains, based on the total weight of the composition, 0.01 to 99.99% of the compound, its medicinal salt, or its isotopic derivative. In one embodiment, the pharmaceutical composition contains 0.1 to 99.9% of the compound, its medicinal salt, or its isotopic derivative. In one embodiment, the pharmaceutical composition contains 0.5 to 99.5% of the compound, its medicinal salt, or its isotopic derivative. In one embodiment, the pharmaceutical composition contains 1 to 99% of the compound, its medicinal salt, or its isotopic derivative. In one embodiment, the pharmaceutical composition contains 2 to 98% of the compound, its medicinal salt, or its isotopic derivative.

[0200] In some embodiments, the pharmaceutical composition contains 0.01% to 99.99% pharmaceutically acceptable excipients, based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1% to 99.9% pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition contains 0.5% to 99.5% pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition contains 1% to 99% pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition contains 2% to 98% pharmaceutically acceptable excipients.

[0201] Pharmaceutically acceptable salts of the compounds described in the present disclosure may be selected from inorganic salts or organic salts.

[0202] Tablets contain the active ingredient and non-toxic, medicament-acceptable excipients suitable for compounding into tablets. These excipients may be inert fillers, granulating agents, disintegrating agents, binders, and lubricants. These tablets may be uncoated or may be coated by known techniques to mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained-release effect over an extended period of time.

[0203] Oral formulations may be provided in soft gelatin capsules containing the active ingredient mixed with an inert solid diluent, or with a water-soluble carrier or oily solvent.

[0204] Aqueous suspensions contain the active substances and mixing excipients suitable for the preparation of aqueous suspensions. Such excipients are suspending, dispersing or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.

[0205] Oil suspensions can be prepared by suspending the active ingredient in vegetable oil or mineral oil.Oil suspensions can also contain thickeners.To provide a palatable preparation, the above-mentioned sweeteners and flavoring agents can also be added.These compositions can be preserved by adding antioxidants.

[0206] The pharmaceutical compositions of the present disclosure may be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil or a mineral oil or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsion may contain sweeteners, flavoring agents, preservatives, and antioxidants. Such formulations may also contain emollients, preservatives, coloring agents, and antioxidants.

[0207] The pharmaceutical compositions of the present disclosure may be in the form of a sterile injectable aqueous solution. Acceptable solvents or vehicles that can be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may also be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase. The injectable solution or microemulsion can be infused into the patient's bloodstream by local injection of a large volume. Alternatively, solutions and microemulsions are preferably administered in a manner that maintains a constant, cyclical concentration of the compounds of the present disclosure. To maintain such a constant concentration, a continuous intravenous infusion device can be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous infusion pump.

[0208] The pharmaceutical compositions of the present disclosure may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration. Such suspensions can be prepared according to known techniques using suitable dispersing or wetting agents and suspending agents as described above. Sterile injectable preparations may be sterile injectable solutions or suspensions prepared in non-toxic parenterally acceptable diluents or solvents. Sterile fixed oils can also be conveniently used as solvents or suspending media. Any suitable fixed oil for formulation can be used for this purpose. Fatty acids can also be used to prepare injectables.

[0209] The compounds of the present disclosure may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid in the rectum, thereby melting in the rectum to release the drug.

[0210] The compounds of the present disclosure can be administered by adding water to prepare dispersible powders and granules in aqueous suspension. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersing or wetting agent, a suspending agent, and one or more preservatives.

[0211] As is well known to those skilled in the art, the dosage of a drug depends on many factors, including, but not limited to, the activity of the specific compound used, the severity of the disease, the patient's age, the patient's weight, the patient's physical condition, the patient's behavior, the patient's diet, the administration time, the administration method, the excretion rate, the composition of the drug, etc. Furthermore, the optimal treatment method, such as the treatment mode, the daily dosage of the compound or the type of medicinal salt, can be verified according to conventional treatment plans.

[0212] Terminology Unless specifically stated to the contrary, terms used in the specification and claims have the following meanings.

[0213] The term "alkyl group" refers to a saturated, straight- or branched-chain aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20 The alkyl group is an alkyl group having 1 to 12 carbon atoms (i.e., C 1-12 alkyl group) is preferred, and alkyl groups having 1 to 6 carbon atoms (i.e., C 1-6alkyl groups) are more preferred. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, Examples of the alkyl groups include 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. The alkyl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably one or more selected from D atoms, halogens, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclyloxy groups, hydroxy groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclyl groups, aryl groups, and heteroaryl groups.

[0214] The term "alkylene group" refers to a divalent alkyl group, wherein alkyl is as defined above, having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20 The alkylene group is an alkylene group having 1 to 12 carbon atoms (i.e., C 1-12 alkylene groups) are preferred, and alkylene groups having 1 to 6 carbon atoms (i.e., C 1-6 Alkylene groups) are more preferred. Non-limiting examples include -CH-, -CH(CH)-, -CH(CH)-, -CHCH-, -CH(CH)-, -CHCH-, -CH(CHCH)-, -CHCH(CH)-, -CHCHCH(CH)-, -CHCHCH-, -CHCHCHCH-, and the like. The alkylene group may be substituted or unsubstituted, and if substituted, it may be substituted at any available point of attachment, and the substituent is preferably one or more selected from a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxy group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0215] The term "alkenyl group" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, where alkyl is as defined above, and having 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) carbon atoms (i.e., C 2-12 The alkenyl group is an alkenyl group having 2 to 6 carbon atoms (i.e., C 2-6Alkenyl groups are preferred. Non-limiting examples include vinyl, propenyl, isopropenyl, butenyl, etc. The alkenyl group may be substituted or unsubstituted, and if substituted, it may be substituted at any available point of attachment, and the substituent is preferably one or more selected from a D atom, an alkoxy group, a halogen, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxy group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0216] The term "alkynyl group" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above, and having 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) carbon atoms (i.e., C 2-12 The alkynyl group is an alkynyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl groups are preferred. Non-limiting examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. The alkynyl group may be substituted or unsubstituted, and if substituted, it may be substituted at any available point of attachment, and the substituent is preferably one or more selected from a D atom, an alkoxy group, a halogen, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxy group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0217] The term "alkoxy group" refers to an -O-(alkyl group), wherein alkyl is defined above. Non-limiting examples include methoxy, ethoxy, propoxy, and butoxy groups. The alkoxy group may be substituted or unsubstituted, and if substituted, it may be substituted at any available point of attachment, and the substituent is preferably one or more selected from a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxy group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0218] The term "cycloalkyl group" refers to a saturated or partially unsaturated monocyclic all-carbon ring (i.e., a monocyclic cycloalkyl group) or polycyclic ring system (i.e., a polycyclic cycloalkyl group) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered cycloalkyl group). The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 ring atoms (i.e., a 3- to 12-membered cycloalkyl group) or a cycloalkyl group having 3 to 10 ring atoms (i.e., a 3- to 10-membered cycloalkyl group), more preferably a cycloalkyl group having 3 to 8 ring atoms (i.e., a 3- to 8-membered cycloalkyl group), and most preferably a cycloalkyl group having 3 to 6 ring atoms (i.e., a 3- to 6-membered cycloalkyl group).

[0219] The monocyclic cycloalkyl groups include, by way of non-limiting example, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, and cyclooctyl groups.

[0220] The polycyclic cycloalkyl groups include spirocycloalkyl groups, fused cycloalkyl groups and bridged cycloalkyl groups.

[0221] The term "spirocycloalkyl group" refers to a polycyclic ring system in which the rings share one carbon atom (referred to as a spiro atom), and which may contain one or more double bonds within the ring, or which may contain one or more heteroatoms within the ring selected from nitrogen, oxygen, and sulfur (which nitrogen may optionally be oxidized, i.e., to form nitrogen oxides, and which sulfur may optionally be substituted with an oxo group, i.e., to form sulfoxides or sulfones, but which does not include -OO-, -OS-, or -SS-), provided that at least one all-carbocyclic ring is included and the point of attachment is at the all-carbocyclic ring, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered spirocycloalkyl group). The spirocycloalkyl group is preferably a spirocycloalkyl group having 6 to 14 ring atoms (i.e., a 6- to 14-membered spirocycloalkyl group), and more preferably a spirocycloalkyl group having 7 to 10 ring atoms (i.e., a 7- to 10-membered spirocycloalkyl group). The spirocycloalkyl group includes monospirocycloalkyl groups and polyspirocycloalkyl groups (e.g., bisspirocycloalkyl groups), and is preferably a monospirocycloalkyl group or a bisspirocycloalkyl group, and more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered monospirocycloalkyl group. Non-limiting examples include: The connection point can be located anywhere. [ka] Includes:

[0222] The term "fused cycloalkyl group" refers to a polycyclic ring system in which rings share two adjacent carbon atoms, such as a monocyclic cycloalkyl group fused with one or more monocyclic cycloalkyl groups, or a monocyclic cycloalkyl group fused with one or more heterocyclyl groups, aryl groups, or heteroaryl groups, where the point of attachment is on the monocyclic cycloalkyl group, which may contain one or more double bonds within the ring, and which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused cycloalkyl group). The fused cycloalkyl group is preferably a fused cycloalkyl group having 6 to 14 ring atoms (i.e., a 6- to 14-membered fused cycloalkyl group), and more preferably a fused cycloalkyl group having 7 to 10 ring atoms (i.e., a 7- to 10-membered fused cycloalkyl group). The fused cycloalkyl group includes bicyclic fused cycloalkyl groups and polycyclic fused cycloalkyl groups (e.g., tricyclic fused cycloalkyl groups, tetracyclic fused cycloalkyl groups, etc.), preferably bicyclic fused cycloalkyl groups or tricyclic fused cycloalkyl groups, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered bicyclic fused cycloalkyl groups. Non-limiting examples are: The connection point can be located anywhere. [ka] Includes:

[0223] The term "bridged cycloalkyl group" refers to an all-carbon polycyclic ring system in which the rings share two carbon atoms that are not directly linked to each other, and may contain one or more double bonds within the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., a 5- to 20-membered bridged cycloalkyl group). The bridged cycloalkyl group is preferably a bridged cycloalkyl group having 6 to 14 carbon atoms (i.e., a 6- to 14-membered bridged cycloalkyl group), and more preferably a bridged cycloalkyl group having 7 to 10 carbon atoms (i.e., a 7- to 10-membered bridged cycloalkyl group). The bridged cycloalkyl group includes bicyclic bridged cycloalkyl groups and polycyclic bridged cycloalkyl groups (e.g., tricyclic bridged cycloalkyl groups, tetracyclic bridged cycloalkyl groups, etc.), and is preferably a bicyclic bridged cycloalkyl group or a tricyclic bridged cycloalkyl group. Non-limiting examples include: The connection point can be located anywhere. [ka] Includes.

[0224] The cycloalkyl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably one or more selected from D atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclyloxy groups, hydroxy groups, hydroxyalkyl groups, oxo groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclyl groups, aryl groups and heteroaryl groups.

[0225] The term "heterocyclyl group" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e., a monocyclic heterocyclyl group) or polycyclic heterocyclic ring system (i.e., a polycyclic heterocyclyl group) containing at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur within the ring (wherein the nitrogen is optionally oxidized, i.e., to form a nitrogen oxide, and the sulfur is optionally substituted with an oxo group, i.e., to form a sulfoxide or sulfone, but does not include -OO-, -OS-, or -SS-) and having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered heterocyclyl group). The heterocyclyl group is preferably a heterocyclyl group having 3 to 12 ring atoms (i.e., a 3- to 12-membered heterocyclyl group), more preferably a heterocyclyl group having 3 to 10 ring atoms (i.e., a 3- to 10-membered heterocyclyl group) or a heterocyclyl group having 3 to 8 ring atoms (i.e., a 3- to 8-membered heterocyclyl group), more preferably a heterocyclyl group having 4 to 7 ring atoms (i.e., a 4- to 7-membered heterocyclyl group), more preferably a heterocyclyl group having 3 to 6 ring atoms (i.e., a 3- to 6-membered heterocyclyl group), and most preferably a heterocyclyl group having 5 or 6 ring atoms (i.e., a 5- or 6-membered heterocyclyl group) or a heterocyclyl group having 3 to 4 ring atoms (i.e., a 3- to 4-membered heterocyclyl group).

[0226] Examples of the monocyclic heterocyclyl group include, but are not limited to, pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl groups.

[0227] The polycyclic heterocyclyl groups include spiroheterocyclyl groups, fused heterocyclyl groups and bridged heterocyclyl groups.

[0228] The term "spiroheterocyclyl group" refers to a polycyclic heterocyclic ring system in which the rings share one atom (referred to as a spiro atom), optionally containing one or more double bonds within the ring, and containing at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur within the ring (wherein the nitrogen is optionally oxidized, i.e., to form a nitrogen oxide, and the sulfur is optionally substituted with an oxo group, i.e., to form a sulfoxide or sulfone, but does not include -OO-, -OS-, or -SS-), provided that at least one monocyclic heterocyclyl group is included and the point of attachment is at the monocyclic heterocyclyl group, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered spiroheterocyclyl group). The spiroheterocyclyl group is preferably a spiroheterocyclyl group having 6 to 14 ring atoms (ie, a 6- to 14-membered spiroheterocyclyl group), and more preferably a spiroheterocyclyl group having 7 to 10 ring atoms (ie, a 7- to 10-membered spiroheterocyclyl group). The spiroheterocyclyl group includes monospiroheterocyclyl groups and polyspiroheterocyclyl groups (e.g., bisspiroheterocyclyl groups), preferably a monospiroheterocyclyl group or a bisspiroheterocyclyl group, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered monospiroheterocyclyl group. Non-limiting examples are: [ka] Includes:

[0229] The term "fused heterocyclyl group" refers to a polycyclic heterocyclic ring system in which the rings share two adjacent atoms, optionally containing one or more double bonds within the ring, and containing at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur within the ring, wherein the nitrogen is optionally oxidized, i.e., to form a nitrogen oxide, and the sulfur is optionally substituted with an oxo group, i.e., to form a sulfoxide or sulfone, but is not limited to -OO-, -OS-, or -SS-. (excluding the following), which is a monocyclic heterocyclyl group fused with one or more monocyclic heterocyclyl groups, or a monocyclic heterocyclyl group fused with one or more cycloalkyl groups, aryl groups, or heteroaryl groups, in which the connection point is on the monocyclic heterocyclyl group and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused heterocyclyl group). The above fused heterocyclyl group is preferably a fused heterocyclyl group having 6 to 14 ring atoms (i.e., a 6- to 14-membered fused heterocyclyl group), and more preferably a fused heterocyclyl group having 7 to 10 ring atoms (i.e., a 7- to 10-membered fused heterocyclyl group). The fused heterocyclyl group includes bicyclic and polycyclic fused heterocyclyl groups (e.g., tricyclic fused heterocyclyl groups, tetracyclic fused heterocyclyl groups, etc.), preferably a bicyclic fused heterocyclyl group or a tricyclic fused heterocyclyl group, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered bicyclic fused heterocyclyl group. Non-limiting examples are: [ka] Includes:

[0230] The term "bridged heterocyclyl group" refers to a polycyclic heterocyclic ring system in which the rings share two atoms that are not directly linked, and which optionally contains one or more double bonds within the ring, and which contains at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur within the ring (wherein the nitrogen is optionally oxidized, i.e., to form a nitrogen oxide, and the sulfur is optionally substituted with an oxo group, i.e., to form a sulfoxide or sulfone, but does not include -OO-, -OS-, or -SS-), and which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered bridged heterocyclyl group). The bridged heterocyclyl group is preferably a bridged heterocyclyl group having 6 to 14 ring atoms (i.e., a 6- to 14-membered bridged heterocyclyl group), and more preferably a bridged heterocyclyl group having 7 to 10 ring atoms (i.e., a 7- to 10-membered bridged heterocyclyl group). Depending on the number of rings constituting the heterocyclyl group, it can be divided into a bicyclic bridged heterocyclyl group and a polycyclic bridged heterocyclyl group (e.g., a tricyclic bridged heterocyclyl group, a tetracyclic bridged heterocyclyl group, etc.), and is preferably a bicyclic bridged heterocyclyl group or a tricyclic bridged heterocyclyl group. Non-limiting examples are: [ka] Includes:

[0231] The heterocyclyl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably one or more selected from D atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclyloxy groups, hydroxy groups, hydroxyalkyl groups, oxo groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclyl groups, aryl groups and heteroaryl groups.

[0232] The term "aryl group" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aryl group) or a polycyclic aromatic ring system (i.e., a polycyclic aryl group) having a conjugated π-electron system and 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 6- to 14-membered aryl group). The aryl group is preferably an aryl group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aryl group). An example of the monocyclic aryl group is a phenyl group. Non-limiting examples of the polycyclic aryl group include a naphthyl group, an anthryl group, and a phenanthryl group. The polycyclic aryl groups further include a phenyl group fused to one or more heterocyclyl or cycloalkyl groups, or a naphthyl group fused to one or more heterocyclyl or cycloalkyl groups, where the point of attachment is at the phenyl or naphthyl group, and in this case the number of ring atoms still refers to the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include: [ka] Includes:

[0233] The aryl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably one or more selected from D atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclyloxy groups, hydroxy groups, hydroxyalkyl groups, oxo groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclyl groups, aryl groups, and heteroaryl groups.

[0234] The term "heteroaryl group" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl group) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl group) having a conjugated π-electron system and containing at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur within the ring (the nitrogen may optionally be oxidized, i.e., to form a nitrogen oxide, and the sulfur may optionally be substituted with an oxo group, i.e., to form a sulfoxide or sulfone, but does not include -OO-, -OS-, or -SS-), and having 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl group). The heteroaryl group is preferably a heteroaryl group having 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl group), and more preferably a heteroaryl group having 5 or 6 ring atoms (i.e., a 5- or 6-membered heteroaryl group).

[0235] Non-limiting examples of the monocyclic heteroaryl group include furanyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, and N-alkylpyridone (e.g., [ka] etc.), pyrazinyl group, pyridazinyl group, etc.

[0236] Non-limiting examples of the polycyclic heteroaryl group include indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalyl, phthalazinyl, benzimidazolyl, benzothienyl, quinazolinyl, benzothiazolyl, carbazolyl, etc. The polycyclic heteroaryl group also includes a monocyclic heteroaryl group fused with one or more aryl groups, where the connection point is on the aromatic ring, and in this case the number of ring atoms still indicates the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl group also includes a monocyclic heteroaryl group fused with one or more cycloalkyl or heterocyclyl groups, where the connection point is on the monocyclic heteroaromatic ring, and in this case the number of ring atoms still indicates the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include: [ka] Includes:

[0237] The heteroaryl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably one or more selected from D atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclyloxy groups, hydroxy groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclyl groups, aryl groups, and heteroaryl groups.

[0238] The term "amino-protecting group" refers to a group that is easily removed and introduced into an amino group to prevent the amino group from being altered when other parts of the molecule react. Non-limiting examples include (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethyloxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), methoxycarbonyl, ethoxycarbonyl, phthaloyl (Pht), p-toluenesulfonyl (Tos), tert-butylsulfinyl, trifluoroacetyl (Tfa), trichloroacetyl, trityl (Trt), 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB), acetyl, benzyl, allyl, p-methoxybenzyl, and the like.

[0239] The term "hydroxy-protecting group" refers to a labile group introduced into a hydroxy group to react with another functional group of a compound in order to block or protect the hydroxy group. Non-limiting examples include trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitrobenzoyl, and the like.

[0240] The term "cycloalkylalkyl group" refers to an alkyl group substituted with one or more cycloalkyl groups, wherein the cycloalkyl group and the alkyl group are as defined above.

[0241] The term "heterocyclylalkyl group" refers to an alkyl group substituted with one or more heterocyclyl groups, wherein the heterocyclyl group, alkyl group are as defined above.

[0242] The term "alkoxyalkyl group" refers to an alkyl group substituted with one or more alkoxy groups, wherein the alkoxy group and the alkyl group are as defined above.

[0243] The term "cycloalkyloxy" refers to a cycloalkyl-O- group, in which the cycloalkyl group is as defined above.

[0244] The term "heterocyclyloxy" refers to a heterocyclyl-O- group, wherein the heterocyclyl group is as defined above.

[0245] The term "aryloxy group" refers to an aryl-O- group, in which the aryl group is as defined above.

[0246] The term "heteroaryloxy" refers to a heteroaryl-O-, wherein the heteroaryl group is as defined above.

[0247] The term "alkylthio" refers to alkyl-S-, in which the alkyl group is as defined above.

[0248] The term "haloalkyl group" refers to an alkyl group substituted with one or more halogens, wherein the alkyl group is as defined above.

[0249] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein the alkoxy group is as defined above.

[0250] The term "deuterated alkyl group" refers to an alkyl group substituted with one or more deuterium atoms, wherein the alkyl group is as defined above.

[0251] The term "hydroxyalkyl group" refers to an alkyl group substituted with one or more hydroxy groups, wherein the alkyl group is as defined above.

[0252] The term "hydroxyalkoxy group" refers to an alkoxy group substituted with one or more hydroxy groups, wherein the alkyl group is as defined above.

[0253] The term "methylene group" refers to =CH2.

[0254] The term "deuterated methyl group" refers to a methyl group substituted with one or more deuterium atoms, for example, CHD2, CH2D and CD3, preferably CD3.

[0255] The term "deuterated methoxy group" refers to an -O-deuterated methyl group, where deuterated methyl group is as defined above, for example, OCD3.

[0256] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0257] The term "hydroxy group" refers to -OH.

[0258] The term "mercapto" refers to -SH.

[0259] The term "amino group" refers to -NH2.

[0260] The term "cyano" refers to -CN.

[0261] The term "nitro group" refers to -NO2.

[0262] The term "oxo" or "oxo group" refers to "=O".

[0263] The term "carbonyl group" refers to C=O.

[0264] The term "acetyl group" refers to -C(O)CH3.

[0265] The term "amide group" refers to -C(O)NH2.

[0266] The term "carboxy" refers to -C(O)OH.

[0267] The term "carboxylic acid ester group" refers to a -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O-, or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.

[0268] Compounds according to the present disclosure may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers that have identical structure but differ in the arrangement of atoms in space. This includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers, and mixtures thereof (e.g., racemates, diastereomeric mixtures). Substituents in compounds according to the present disclosure may contain other asymmetric atoms. All such stereoisomers and mixtures thereof are within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers, and (D)- and (L)-isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. Single isomers of certain compounds of the present disclosure can be prepared by asymmetric synthesis or chiral auxiliaries, or, if the molecule contains a basic functional group (e.g., an amino group) or an acidic functional group (e.g., a carboxy group), by forming a diastereomeric salt with an appropriate optically active acid or base and then diastereomeric separation by conventional methods known in the art to obtain pure isomers. Furthermore, separation of enantiomers and diastereomers is typically accomplished by chromatography.

[0269] In the chemical structures of the compounds described in this disclosure, [ka] indicates that the configuration is not specified, i.e., chiral isomers exist in the chemical structure, [ka] The bond [ka] or [ka] In the chemical structure of the compound described in the present disclosure, [ka] The bond may have no specified configuration, i.e., it may have the Z or E configuration, or it may contain both configurations simultaneously. Any carbon-carbon double bond may have both the Z and E configurations even if only one configuration is named. [ka] The bond "Z" is unspecified, ie, it may be in the Z or E configuration, or it may include both configurations simultaneously.

[0270] In the chemical structures of the compounds described in this disclosure, the bond connecting the stereoisomeric center of the compound [ka] ,for example, [ka] indicates the relative configuration of the stereoisomeric center, and compound 1a in Example 1 is a mixture of 1b-1 and 1b-2.

[0271] The compounds of the present disclosure may exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to a structural isomer that exists in equilibrium and in which one isomeric form is easily converted from one to the other. It includes all possible tautomers, i.e., existing in the form of a single isomer or a mixture of said tautomers in any ratio. Non-limiting examples include keto-enol, imine-enamine, lactam-lactim, etc. An example of an enamine-imine equilibrium is as follows: [ka]

[0272] Amidines, also known as iminoamides, are compounds in which the carbonyl oxygen atom in an imide molecule is replaced with an imino group. The imide group and amino group of an amidine can be converted into each other to form tautomers. The tautomers of amidine are as follows: [ka]

[0273] For example, a reference to a pyrazolyl group should be understood to include any one or a mixture of two tautomers of the following two structures: [ka]

[0274] All tautomeric forms are within the scope of the present disclosure, and the naming of a compound does not exclude any tautomeric form.

[0275] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds. The term "isotopic derivative" refers to a compound in which at least one atom has been replaced with an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be incorporated into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13 C. 14 C. 15 N, 17 O. 18 O. 32 p, 33 p, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 129 I and 131 I, and deuterium is preferred.

[0276] Compared with non-deuterated drugs, deuterated drugs have the advantages of reduced toxicity and side effects, increased drug stability, improved therapeutic efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are included within the scope of the present disclosure. Each available hydrogen atom connected to a carbon atom may be independently replaced with a deuterium atom, where deuterium substitution may be partial or complete, and partial deuterium substitution means that at least one hydrogen is replaced with at least one deuterium.

[0277] When a position of a compound according to the present disclosure is specifically designated as "deuterium" or "D," it should be understood that the position has an abundance of deuterium at least 1000 times greater than the natural abundance of deuterium (i.e., at least 15% deuterium incorporated) than the natural abundance of deuterium (which is 0.015%). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 1000 times greater than the natural abundance of deuterium (i.e., at least 15% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 2000 times greater than the natural abundance of deuterium (i.e., at least 30% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 3000 times greater than the natural abundance of deuterium (i.e., at least 45% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 3340 times greater than the natural abundance of deuterium (i.e., at least 50.1% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 3500 times greater than the natural abundance of deuterium (i.e., at least 52.5% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 4000 times greater than the natural abundance of deuterium (i.e., at least 60% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 4500 times greater than the natural abundance of deuterium (i.e., at least 67.5% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 5000 times greater than the natural abundance of deuterium (i.e., at least 75% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 5500 times greater than the natural abundance of deuterium (i.e., at least 82.5% deuterium incorporated), hi some embodiments, each designated deuterium atom has an abundance of deuterium at least 6000 times greater than the natural abundance of deuterium (i.e., at least 90% deuterium incorporated).In some embodiments, each designated deuterium atom has an abundance of deuterium at least 6333.3 times greater than the natural abundance of deuterium (i.e., at least 95% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 6466.7 times greater than the natural abundance of deuterium (i.e., at least 97% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 6600 times greater than the natural abundance of deuterium (i.e., at least 99% deuterium incorporated). In some embodiments, each designated deuterium atom has an abundance of deuterium at least 6633.3 times greater than the natural abundance of deuterium (i.e., at least 99.5% deuterium incorporated).

[0278] "Optionally" or "optionally" means that the event or circumstance described thereafter may or may not occur, and includes both cases where the event or circumstance occurs and where it does not occur. For example, "an alkyl group optionally (arbitrarily) substituted with a halogen or a cyano group" includes cases where the alkyl group is substituted with a halogen or a cyano group and cases where the alkyl group is not substituted with a halogen or a cyano group.

[0279] "Substituted" or "substituted" refers to one or more hydrogen atoms, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms in a group, being independently replaced with a corresponding number of substituents. Those skilled in the art can determine (experimentally or theoretically) possible or impossible substitutions without much effort. For example, an amino group or a hydroxy group having free hydrogen may be unstable when bonded to a carbon atom having an unsaturated bond (e.g., an olefin).

[0280] The term "pharmaceutical composition" refers to a mixture of one or more compounds described herein or their pharmaceutically acceptable salts with other chemical components, and other components such as pharmaceutically acceptable carriers and excipients, which facilitate administration to a living body and contribute to the absorption of the active ingredients to further exert their biological activity.

[0281] "Pharmaceutically acceptable salt" refers to a salt of a compound according to the present disclosure, and may be selected from inorganic salts or organic salts. Such salts are safe and effective when used in a mammalian body, and have the desired biological activity. They may be prepared during the final isolation and purification process of the compound, or separately by reacting a suitable group with a suitable base or acid. Generally, bases for forming pharmaceutically acceptable salts include inorganic bases such as sodium hydroxide and potassium hydroxide, and organic bases such as ammonium. Generally, acids for forming pharmaceutically acceptable salts include inorganic acids and organic acids.

[0282] As used herein, the term "pharmaceutically acceptable" means that these compounds, materials, compositions and / or dosage forms are, within the scope of reasonable medical judgment, applicable to contact with the tissues of patients without undue toxicity, irritation, allergic response or other problem or complication, and are effective for the desired use, with a reasonable benefit / risk ratio.

[0283] As used herein, the singular forms "a," "an," and "the" include plural references and vice versa unless the context clearly indicates otherwise.

[0284] The term "about," when used with respect to parameters such as pH, concentration, temperature, etc., indicates that the parameter may be varied within ±10%, and in some cases more preferably ±5%. As will be understood by those skilled in the art, when a parameter is not critical, generally the number is given merely for illustration, not limitation.

[0285] Methods for synthesizing compounds according to the present disclosure To achieve the objectives of the present disclosure, the present disclosure adopts the following technical solutions:

[0286] Technical proposal 1 The present disclosure provides a method for preparing a compound of general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (Ia) or a salt thereof and a compound represented by general formula (Ib) or a salt thereof to a condensation reaction under basic conditions to obtain a compound represented by general formula (I) or a medicamentable salt thereof, R 10 is a halogen (preferably a chlorine atom) or OH, Among them, R 10 When is OH, the reaction occurs in the presence of a condensing agent, Ring A, R A , R', R a , R b , R c , R d , R e , X, X 1 , X 2 , X 3 , X 4 , X 5 and r are as defined in general formula (I).

[0287] Technical proposal 1-1 The present disclosure provides a method for preparing a compound of general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IA') or a salt thereof and a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to a Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (I) or a medicamentable salt thereof, Preferably, the method comprises reacting a compound represented by general formula (IA') or a salt thereof and a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) with mercaptoacetic acid in the presence of a base to obtain a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein: At least one R in general formula (I) A is -C(=NH)NR 5 -OR 6 or -C(=NH)NR 3 R 4 and r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; Remaining R A is as defined in general formula (I), Ring A, R', R a , R b , R c , R d , R e , X, X 1 , X 2 , X 3 , X 4 , X 5 , R 3 , R 4 , R 5 and R 6 is as defined in general formula (I).

[0288] Technical proposal 2 The present disclosure provides a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof to a condensation reaction with a compound represented by general formula (Ib) or a salt thereof under basic conditions to obtain a compound represented by general formula (II) or a medicamentable salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, Among them, R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, Ring A, R A , R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 and r are as defined in general formula (II).

[0289] Technical proposal 2-1 The present disclosure provides a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIA') or a salt thereof and a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to a Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (II) or a medicamentable salt thereof, Preferably, the method comprises reacting a compound represented by general formula (IIA') or a salt thereof and a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) with mercaptoacetic acid in the presence of a base to obtain a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, wherein: At least one R in general formula (II) A is -C(=NH)NR 5 -OR 6 or -C(=NH)NR 3 R 4 and r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; Remaining R A is as defined in general formula (II), Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and R 6 is as defined in general formula (II).

[0290] Technical proposal 2-2 The present disclosure provides a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IIa') or a salt thereof with an amine or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (II) or a medicament-use salt thereof, wherein: The above amines are 5 -OR 6 , HNR 5 -NR 3 R 4 and HNR 5 -alkylene-Cy; R* is selected from a hydroxy group, an alkoxy group, and a halogen; At least one R in general formula (II) A is -C(O)NR 5 -OR 6 , -C(O)NR 5 -NR 3 R 4 and -C(O)NR 5 -alkylene-Cy; Remaining R A is as defined in general formula (II), r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; Ring A, R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 , R 6 and Cy are as defined in general formula (II).

[0291] Technical proposal 2-3 The present disclosure provides a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: X1is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (II) or a pharmaceutical salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (II) or a pharmaceutically acceptable salt thereof, wherein is -OH.

[0292] Technical proposal 2-4 The present disclosure provides a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IIA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) by Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, At least one R in general formula (II) A is -C(=NR 5 )NR 3 R 4 and r is 1, 2, 3, 4 or 5, and r-1 is 0, 1, 2, 3 or 4; R 3 and R 4 are both hydrogen atoms, Remaining R A is as defined in general formula (II), Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 and R 5 is as defined in general formula (II).

[0293] Technical proposal 2-A The present disclosure provides a method for preparing a compound of general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIA') or a salt thereof and a compound represented by general formula (II'B) or a salt thereof (preferably hydrochloride) to a Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (II') or a medicamentable salt thereof, wherein: R 5 is a hydrogen atom, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3a , R 4 and r-1 are as defined in general formula (II').

[0294] Technical proposal 2-A1 The present disclosure provides a method for preparing a compound of general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof and a compound represented by general formula (II'b) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (II') or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3a , R 4 , R 5 and r-1 are as defined in general formula (II').

[0295] Technical proposal 2-A2 The present disclosure provides a method for preparing a compound of general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (II') or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (II') or a pharmaceutically acceptable salt thereof, wherein is -OH.

[0296] Technical proposal 2-A3 The present disclosure provides a method for preparing a compound of general formula (II') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IIA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) is subjected to a Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (II') or a medicament salt thereof, R 3a and R 4 are both hydrogen atoms, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 5 and r-1 are as defined in general formula (II').

[0297] Technical proposal 2-B The present disclosure provides a method for preparing a compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IIa') or a salt thereof with a compound represented by general formula (II-1B) or a salt thereof (preferably hydrochloride) under basic conditions to obtain a compound represented by general formula (II-1) or a medicamentable salt thereof, wherein: R* is selected from a hydroxy group, an alkoxy group, and a halogen; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and r-1 are as defined in general formula (II-1).

[0298] Technical proposal 2-B1 The present disclosure provides a method for preparing a compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof and a compound represented by general formula (II-1b) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (II-1) or a medicamentable salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, Ring A, R A , R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R4 , R 5 and r-1 are as defined in general formula (II-1).

[0299] Technical proposal 2-B2 The present disclosure provides a method for preparing a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (II-1) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof, wherein is —OH.

[0300] Technical proposal 3 The present disclosure provides a method for preparing a compound of general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises hydrolyzing a compound represented by general formula (IIIA) or a salt thereof under acidic conditions to obtain a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, wherein: R 12 and R 13 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group and a phenyl group, and preferably, R 12 and R 13 are the same or different and each independently represent a hydrogen atom, C 1-6 alkyl groups and 5- or 6-membered cycloalkyl groups, most preferably R 12 and R 13 are both CH3, Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 and t are as defined in general formula (III).

[0301] Technical proposal 3-1 The present disclosure provides a method for preparing a compound of general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (III) or a pharmaceutically acceptable salt thereof, wherein is -OH.

[0302] Technical proposal 4 The present disclosure provides a method for preparing a compound represented by general formula (III-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises hydrolyzing a compound represented by general formula (IIIA-1) or a salt thereof under acidic conditions to obtain a compound represented by general formula (III-1) or a medicament-use salt thereof, wherein: R 12 and R 13 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group and a phenyl group, and preferably, R 12 and R 13 are the same or different and each independently represent a hydrogen atom, C 1-6 alkyl groups and 5- or 6-membered cycloalkyl groups, most preferably R 12 and R 13 are both CH3, Ring A, R', R a , R b , R c , R d , X, R X1 , R X2 , R X3 and t are as defined in general formula (III-1).

[0303] Technical proposal 4-1 The present disclosure provides a method for preparing a compound of general formula (III-1) or a pharmaceutically acceptable salt thereof, the method comprising: X1is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (III-1) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (III-1) or a pharmaceutically acceptable salt thereof, wherein is —OH.

[0304] Technical proposal 5 The present disclosure provides a method for preparing a compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (IVb) or a salt thereof to a condensation reaction under basic conditions to obtain a compound represented by general formula (IV) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, Among them, R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A and R 3A is as defined in general formula (IV).

[0305] Technical proposal 5-1 The present disclosure provides a method for preparing a compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises reacting a compound represented by general formula (IVA') or a salt thereof with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) in the presence of a catalyst to obtain a compound represented by general formula (IV) or a medicamentable salt thereof, Preferably, the method comprises reacting a compound represented by general formula (IVA') or a salt thereof and a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) with mercaptoacetic acid in the presence of a base to obtain a compound represented by general formula (IV) or a medicamentable salt thereof, wherein: R 3A is -C(=NH)NR 5 -OR 6 or -C(=NH)NR 3 R 4 and R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 and R 6 is as defined in general formula (IV).

[0306] Technical proposal 5-2 The present disclosure provides a method for preparing a compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IVa') or a salt thereof with an amine or a salt thereof (preferably hydrochloride) under basic conditions to obtain a compound represented by general formula (IV) or a medicamentable salt thereof, wherein: The above amines are 5 -OR 6 , HNR 5 -NR 3 R 4 and HNR 5 -alkylene-Cy; R* is selected from a hydroxy group, an alkoxy group, and a halogen; R 3A is -C(O)NR 5 -OR 6 , -C(O)NR 5 -NR3 R 4 and -C(O)NR 5 -alkylene-Cy; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 , R 5 , R 6 and Cy are as defined in general formula (IV).

[0307] Technical proposal 5-3 The present disclosure provides a method for preparing a compound of general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (IV) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0308] Technical proposal 5-4 The present disclosure provides a method for preparing a compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IVA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) in the presence of a catalyst to obtain a compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, R 3A is -C(=NR 5 )NR 3 R 4 and R 1A , R2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 and R 5 is as defined in general formula (IV).

[0309] Technical proposal 6 The present disclosure provides a method for preparing a compound represented by general formula (V) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof to a condensation reaction with a compound represented by general formula (Vb) or a salt thereof to obtain a compound represented by general formula (V) or a medicamentable salt thereof, wherein: R W1 is a hydrogen atom or an amino-protecting group (preferably a tert-butylsulfinyl group), and R W2 is a hydrogen atom or a hydroxy protecting group (preferably TBS), R W1 is an amino protecting group, and / or R W2 is a hydroxy protecting group, the preparation method further comprises the step of removing the protecting group under acidic conditions after the condensation reaction; R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V).

[0310] Technical proposal 6-1 The present disclosure provides a method for preparing a compound of general formula (V) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0311] Technical proposal 7 The present disclosure provides a method for producing a compound represented by general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (V-1b) or a salt thereof are subjected to a condensation reaction under basic conditions to obtain a compound represented by general formula (V-1) or a medicamentable salt thereof, or The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (V-2b) or a salt thereof to a condensation reaction under basic conditions to obtain a compound represented by general formula (V-2) or a medicamentable salt thereof, wherein R W1 is a hydrogen atom or an amino-protecting group (preferably tert-butylsulfinyl), and R W2 is a hydrogen atom or a hydroxy protecting group (preferably TBS), R W1 is an amino protecting group, and / or R W2 is a hydroxy protecting group, the preparation method further comprises the step of removing the protecting group under acidic conditions after the condensation reaction; R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R a , R b , R c , R d , R X1 , RX2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V-1).

[0312] Technical proposal 7-1 The present disclosure provides a method for preparing a compound represented by general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, wherein is —OH.

[0313] Technical proposal 8 The present disclosure provides a method for producing a compound represented by general formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (V-1A) or a salt thereof is subjected to a deprotection reaction under acidic conditions to obtain a compound represented by general formula (V-1) or a medicamentable salt thereof, The method comprises deprotecting a compound represented by general formula (V-2A) or a salt thereof under acidic conditions to obtain a compound represented by general formula (V-2) or a medicament-use salt thereof, wherein: R W1 is an amino protecting group, and the amino protecting group is preferably Boc; R a , R b , R c , R d , R X1 , R X2 , R X3 , R', R 1A , R 2A , R A4 , u1 and u2 are as defined in general formula (V-1).

[0314] Technical proposal 9-A1 The present disclosure provides a method for preparing a compound of general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (VI'B) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VI') or a medicamentable salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 , R 4 and R 5 is as defined in general formula (VI').

[0315] Technical proposal 9-A2 The present disclosure provides a method for preparing a compound of general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (VI'A) or a salt thereof to a Pinner reaction with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI') or a medicament-use salt thereof, wherein R 5 is a hydrogen atom, R', R a , R b , R c , R d , R X1 , R X2 , RX3 , R 1A , R 2A , Q, R 3 and R 4 is as defined in general formula (VI').

[0316] Technical proposal 9-A3 The present disclosure provides a method for preparing a compound of general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (VI') or a pharmaceutical salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 The method includes obtaining a compound of general formula (VI') or a pharmaceutically acceptable salt thereof, wherein is -OH.

[0317] Technical proposal 9-A4 The present disclosure provides a method for preparing a compound of general formula (VI') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (VI'A) or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) by Pinner reaction to obtain a compound represented by general formula (VI') or a pharmaceutically acceptable salt thereof, R 3 and R 4 are both hydrogen atoms, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q and R 5 is as defined in general formula (VI').

[0318] Technical proposal 9-A-A1 The present disclosure provides a method for preparing a compound represented by general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (VI'-1B) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VI'-1) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 , R 5 and R C is as defined in general formula (VI'-1).

[0319] Technical proposal 9-A-A2 The present disclosure provides a method for preparing a compound represented by general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (VI'A) or a salt thereof to a Pinner reaction with a compound represented by general formula (VI-1B') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI'-1) or a medicament-use salt thereof, wherein R 5 is a hydrogen atom, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R Cis as defined in general formula (VI'-1).

[0320] Technical proposal 9-A-A3 The present disclosure provides a method for preparing a compound represented by general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (VI') or a salt thereof (preferably trifluoroacetate) with a compound represented by general formula (VI'-1b) or a salt thereof (preferably hydrochloride) under basic conditions to obtain a compound represented by general formula (VI'-1) or a medicamentable salt thereof, wherein R 4 is a hydrogen atom, R 10 is halogen (preferably chlorine) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 , R 5 and R C is as defined in general formula (VI'-1).

[0321] Technical proposal 9-A-A4 The present disclosure provides a method for preparing a compound represented by general formula (VI'-1) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (VI'-1) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0322] Technical proposal 9 The present disclosure provides a method for preparing a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVA') or a salt thereof and a compound represented by general formula (II'B) or a salt thereof (preferably hydrochloride) to a Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (VI) or a medicamentable salt thereof, wherein: R 5 is a hydrogen atom, R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3a and R 4 is as defined in general formula (VI).

[0323] Technical proposal 9-1 The present disclosure provides a method for preparing a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (VIb) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VI) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R1A , R 2A , R 3a , R 4 and R 5 is as defined in general formula (VI).

[0324] Technical proposal 9-2 The present disclosure provides a method for preparing a compound of general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (VI) or a pharmaceutical salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0325] Technical proposal 9-3 The present disclosure provides a method for preparing a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] A compound represented by general formula (IVA') or a salt thereof and NH2-R 5 or a salt thereof (preferably hydrochloride) by Pinner reaction in the presence of a catalyst to obtain a compound represented by general formula (VI) or a pharmaceutically acceptable salt thereof, R 3a and R 4 are both hydrogen atoms, R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 and R 5 is as defined in general formula (VI).

[0326] Technical proposal 10-A1 The present disclosure provides a method for preparing a compound represented by general formula (VII') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (VII'B) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VII') or a medicamentable salt thereof, wherein: R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , R 3 , R 4 and R 5 is as defined in general formula (VII').

[0327] Technical proposal 10-A2 The present disclosure provides a method for preparing a compound represented by general formula (VII') or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (VII') or a salt thereof and a compound represented by general formula (II-1B) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VII') or a medicamentable salt thereof, wherein: R* is selected from a hydroxy group, an alkoxy group, and a halogen; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; R', R a , R b , R c , R d , R X1 , R X2 , R X3, R 1A , R 2A , Q, R 3 , R 4 and R 5 is as defined in general formula (VII').

[0328] Technical proposal 10-A3 The present disclosure provides a method for preparing a compound of general formula (VII') or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (VII') or a medicament salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0329] Technical proposal 10 The present disclosure provides a method for preparing a compound represented by general formula (VII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises amidating a compound represented by general formula (IVa') or a salt thereof with a compound represented by general formula (II-1B) or a salt thereof (preferably hydrochloride) under basic conditions to obtain a compound represented by general formula (VII) or a medicamentable salt thereof, wherein R* is selected from a hydroxy group, an alkoxy group, and a halogen; When the amino group contains a protecting group, the method further comprises removing the protecting group, the amino protecting group being preferably Boc; R 1A , R 2A , R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 3 , R 4 and R 5 is as defined in general formula (VII).

[0330] Technical proposal 10-1 The present disclosure provides a method for preparing a compound represented by general formula (VII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IVa) or a salt thereof and a compound represented by general formula (VIIb) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VII) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , R 3 , R 4 and R 5 is as defined in general formula (VII).

[0331] Technical proposal 10-2 The present disclosure provides a method for preparing a compound of general formula (VII) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (VII) or a pharmaceutical salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0332] Technical proposal 11-1 The present disclosure provides a method for preparing a compound represented by general formula (VIII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (IIa) or a salt thereof and a compound represented by general formula (VIIIB) or a salt thereof (preferably hydrochloride) to a condensation reaction under basic conditions to obtain a compound represented by general formula (VIII) or a medicamentable salt thereof, wherein R 10 is a halogen (preferably a chlorine atom) or OH, and R 10 When is OH, the reaction occurs in the presence of a condensing agent or oxalyl chloride, preferably in the presence of a condensing agent, R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R 4 is as defined in general formula (VIII).

[0333] Technical proposal 11-2 The present disclosure provides a method for preparing a compound represented by general formula (VIII) or a pharmaceutically acceptable salt thereof, the method comprising: [ka] The method comprises subjecting a compound represented by general formula (VIIIA) or a salt thereof to a urethane exchange reaction with a compound represented by general formula (IB') or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VIII) or a medicamentable salt thereof, wherein R L is an alkoxy group, R', X, R a , R b , R c , R d , R X1 , R X2 , R X3 , R 1A , R 2A , Q, R 3 and R 4 is as defined in general formula (VIII).

[0334] Technical proposal 11-3 The present disclosure provides a method for preparing a compound of general formula (VIII) or a pharmaceutically acceptable salt thereof, the method comprising: X1 is an alkoxy group or a cycloalkoxy group, the compound represented by the general formula (VIII) or a pharmaceutically acceptable salt thereof is subjected to a dealkylation or decycloalkylation reaction under acidic conditions to obtain R X1 is -OH or a pharmaceutically acceptable salt thereof.

[0335] The Pinner reaction is based on the Pinner amidine synthesis method, and its specific mechanism is as follows: a cyanide compound, which is the raw material, undergoes an alcoholysis reaction with an alcohol solvent under the catalytic action of a catalyst to produce an iminoester, which is then subjected to an aminolysis or ammonolysis reaction with an amine or ammonia to produce an amidine.

[0336] The catalyst described in the Pinner reaction above may be an acid catalyst or a base catalyst, and the acid catalyst is an organic acid or an inorganic acid, including but not limited to hydrochloric acid, hydrogen chloride gas, mercaptoacetic acid, and N-acetylcysteine, and preferably mercaptoacetic acid. The base catalyst is an organic base or an inorganic base, including but not limited to sodium methoxide, sodium ethoxide, triethylamine, N,N-diisopropylethylamine, N,N-diisopropylethylenediamine, and preferably N,N-diisopropylethylamine or sodium methoxide, and more preferably sodium methoxide.

[0337] The ammonia used in the ammonolysis reaction is liquid ammonia, aqueous ammonia, or an ammonium salt, preferably ammonium chloride, and the amine used in the aminolysis reaction is an organic amine.

[0338] The alcohol solvent includes, but is not limited to, methanol, ethanol, isopropanol, and n-butanol.

[0339] In the above synthesis schemes, the reagents for providing acidic conditions include organic acids and inorganic acids, and the organic acids include, but are not limited to, trifluoroacetic acid, formic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, Me3SiCl, and TMSOTf. The inorganic acids include, but are not limited to, hydrogen chloride, HCl-dioxane solution, hydrochloric acid-dioxane solution, hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, preferably HCl-dioxane solution or hydrochloric acid-dioxane solution. In the above synthesis schemes, the reagents for providing acidic conditions in the dealkylation or decycloalkylation reaction are preferably Lewis acids, such as BBr3, ALCl3, etc., and preferably BBr3.

[0340] In the above synthesis scheme, the reagents providing basic conditions include organic bases and inorganic bases, the organic bases include, but are not limited to, triethylamine, N,N-diisopropylethylamine, N,N-diisopropylethylenediamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, potassium tert-butoxide, tetrabutylammonium ...

Claims

1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, 【Chemical 1】 Among them, Ring A is a phenyl group or a 6-membered heteroaryl group; Each R Ａ are the same or different and each independently represent a deuterium atom, a halogen, a hydroxy group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a hydroxyalkoxy group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, -NR ３ R ４ , -alkylene-NR ３ R ４ , —O-alkylene-NR ３ R ４ , -C(=NR ５ ) R ６ , -S(O) ｖ NR ３ R ４ , -NR ５ S (O) ｖ R ６ , -S(O) ｖ R ６ , -S(=NR ５ ) (O) R ６ , -NR ５ C(O)R ６ , -NR ５ C(O)NR ３ R ４ , —C(O)NR ５ -OR ６ , -P(O)R ７ R ８ , —C(O)NR ５ -NR ３ R ４ , -C(=NR ５ ) NR ５ -OR ６ , —C(O)NR ５ -Alkylene-Cy, -C(=NR ５ ) NR ３ R ４ , -C(O)-C(O)-NR ３ R ４ , -S(=NR ５ ) NR ３ R ４ , -S(=NR ５ ) R ６ , -S(=NR ５ ) (O) NR ３ R ４ , —Si(O)NR ３ R ４ , -Si(R ６ ) ３ , -OR ６ , a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a -C(O)-cycloalkyl group, a -C(O)-heterocyclyl group, an -alkylene-O-alkylene-cycloalkyl group, an -alkylene-O-cycloalkyl group, an -O-alkylene-heteroaryl group and an -O-alkylene-heterocyclyl group, wherein said alkyl group, alkoxy group, alkoxyalkyl group, alkenyl group, alkynyl group, alkylene group, cycloalkyl group, heterocyclyl group, aryl group, heteroaryl group, cycloalkylalkyl group and heterocyclylalkyl group each independently and optionally may be selected from the group consisting of ０１ is replaced by Cy is a cycloalkyl group or a heterocyclyl group, and the cycloalkyl group and the heterocyclyl group each independently optionally contain a deuterium atom, a halogen atom, a hydroxyl group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl) ２ , acetyl group, alkyl group, alkenyl group, alkynyl group, alkoxy group, haloalkyl group, haloalkoxy group, hydroxyalkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group, Each R ３ , R ４ and R ５ are the same or different and each independently represent a hydrogen atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, or NR ２０ R ２１ , C(O)NR ２０ R ２１ , N.R. ２２ C(O)R ２３ , C(O)R ２３ , C(O)OR ２３ , O.C.(O.)R ２３ , S(O) ｖ R ２３ , S(O) ｖ OR ２３ , OS(O) ｖ R ２３ , S(O) ｖ NR ２０ R ２１ , OR ２３ , a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group each independently and optionally may be selected from one or more R ０１ is replaced by Or, R ３ , R ４ together with the nitrogen atom to which it is attached form a heterocyclyl group, said heterocyclyl group optionally containing one or more R ０１ is replaced by Each R ６ , R ７ and R ８ are the same or different and each independently represent a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, NR ２０ R ２１ , C(O)NR ２０ R ２１ , N.R. ２２ C(O)R ２３ , C(O)R ２３ , C(O)OR ２３ , O.C.(O.)R ２３ , S(O) ｖ R ２３ , S(O) ｖ OR ２３ , OS(O) ｖ R ２３ , S(O) ｖ NR ２０ R ２１ , OR ２３ , a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an aryl group, and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, cycloalkylalkyl group, heterocyclylalkyl group, aryl group, and heteroaryl group are each independently optionally selected from one or more R ０１ is replaced by Each R ０１ are the same or different and each independently represent a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl) ２ , an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, ═CR ７ａ R ８ａ , -NR ３ R ４ , -alkylene-NR ３ R ４ , —O-alkylene-NR ３ R ４ , -C(=NR ５ ) R ６ , -S(O) ｖ NR ３ R ４ , -NR ５ S (O) ｖ R ６ , -S(O) ｖ R ６ , -S(=NR ５ ) (O) R ６ , -NR ５ C(O)R ６ , -NR ５ C(O)NR ３ R ４ , —C(O)NR ５ -OR ６ , -P(O)R ７ R ８ , —C(O)NR ５ -NR ３ R ４ , -C(=NR ５ ) NR ５ -OR ６ , —C(O)NR ５ -Alkylene-Cy, -C(=NR ５ ) NR ３ R ４ , -C(O)-C(O)-NR ３ R ４ , -S(=NR ５ ) NR ３ R ４ , -S(=NR ５ ) R ６ , -S(=NR ５ ) (O) NR ３ R ４ , —Si(O)NR ３ R ４ , -OR ６ , -Si(R ６ａ ) ３ , -O-alkylene-heteroaryl and -O-alkylene-heterocyclyl groups, wherein the alkyl, alkenyl, alkynyl, alkoxy, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl groups each independently optionally contain a deuterium atom, a halogen, a hydroxyl group, a cyano group, an oxo group, an amino group, an -NH alkyl group, an -N(alkyl) ２ , acetyl group, alkyl group, alkenyl group, alkynyl group, alkoxy group, haloalkyl group, haloalkoxy group, hydroxyalkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group, Each R ６ａ , R ７ａ and R ８ａ are the same or different and each independently represent a hydrogen atom, a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an -NH alkyl group, an -N(alkyl) ２ , an acetyl group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group; R' is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, a cycloalkyl group and a heterocyclyl group; X is O or S; R ａ and R ｂ are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, a deuterated alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a deuterated alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the cycloalkyloxy group and the heterocyclyloxy group may optionally be selected from one or more R ０２ is replaced by However, R ａ and R ｂ is not hydrogen at the same time, R ｃ and R ｄ are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkyloxy group and a heterocyclyloxy group, and the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the cycloalkyloxy group and the heterocyclyloxy group may optionally be selected from one or more R ０２ is replaced by Or, R ａ , R ｂ together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, or R ｃ , R ｄ together with the carbon atom to which it is attached form a cycloalkyl or heterocyclyl group, wherein said cycloalkyl or heterocyclyl group each independently optionally contains one or more R ０２ is replaced by R ｅ is selected from a hydrogen atom, a deuterium atom, a halogen, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a deuterated alkyl group, a deuterated alkoxy group and a hydroxyalkyl group; Each R ０２ are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; Each R ２０ , R ２１ and R ２２ are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; Each R ２３ are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a deuterated alkyl group, an alkoxy group, a deuterated alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are each independently optionally substituted with one or more groups selected from a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group and a hydroxyalkyl group; X １ is CR Ｘ１ or N, X ２ is CR Ｘ２ or N, X ３ is CR Ｘ３ or N, X ４ is CR Ｘ４ or N, X ５ is CR Ｘ５ or N, X １ , X ２ , X ３ , X ４ and X ５ is not N at the same time, R Ｘ１ , R Ｘ２ , R Ｘ３ , R Ｘ４ and R Ｘ５ are the same or different and each independently represent a hydrogen atom, a deuterium atom, a halogen atom, a hydroxy group, a cyano group, an amino group, an amido group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a deuterated alkyl group, a haloalkoxy group, a deuterated alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, -O-(CH ２ ) ｎ -cycloalkyl group, -O-(CH ２ ) ｓ - selected from heterocyclyl groups, aryl groups and heteroaryl groups, wherein said alkyl groups, alkoxy groups, alkenyl groups, alkynyl groups, cycloalkyl groups, heterocyclyl groups, aryl groups and heteroaryl groups each independently and optionally contain one or more R ０３ is replaced by Each R ０３ are the same or different and are each independently selected from a deuterium atom, a halogen, a hydroxy group, a cyano group, an oxo group, an amino group, an amido group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group; each v is the same or different and is independently selected from 0, 1, and 2; n is selected from 0, 1, 2, 3, 4 and 5; s is selected from 0, 1, 2, 3, 4 and 5, and r is selected from 0, 1, 2, 3, 4 and 5, however, 【Chemistry 2】 teeth 【Chemistry 3】 isn't it, The compound or a pharmaceutically acceptable salt thereof.

2. A compound represented by general formula (II) or a medicamentable salt thereof, 【Chemistry 4】 Among them, R ａ and R ｂ are different and each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, an amino group, C １－６ Alkyl group, C ２－６ Alkenyl group, C ２－６ Alkynyl group, C １－６ Alkoxy group, halo C １－６ Alkyl group, halo C １－６ Alkoxy group, C １－６ hydroxyalkyl groups, 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 3- to 10-membered cycloalkyloxy groups and 3- to 10-membered heterocyclyloxy groups, wherein said 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 3- to 10-membered cycloalkyloxy groups and 3- to 10-membered heterocyclyloxy groups are optionally selected from the group consisting of hydroxyalkyl groups, 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 3- to 10-membered cycloalkyloxy groups and 3- to 10-membered heterocyclyloxy groups, ０２ is replaced by R ｃ and R ｄ are different and each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, an amino group, C １－６ Alkyl group, C ２－６ Alkenyl group, C ２－６ Alkynyl group, C １－６ Alkoxy group, halo C １－６ Alkyl group, halo C １－６ Alkoxy group, C １－６ hydroxyalkyl groups, 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 3- to 10-membered cycloalkyloxy groups and 3- to 10-membered heterocyclyloxy groups, wherein said 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 3- to 10-membered cycloalkyloxy groups and 3- to 10-membered heterocyclyloxy groups are optionally selected from the group consisting of hydroxyalkyl groups, 3- to 10-membered cycloalkyl groups, 3- to 10-membered heterocyclyl groups, 3- to 10-membered cycloalkyloxy groups and 3- to 10-membered heterocyclyloxy groups, ０２ is replaced by Ring A, R Ａ , R', X, R Ｘ１ , R Ｘ２ , R Ｘ３ , R ０２ and r are as defined in claim 1; 10. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. Ring A is 【Chemistry 5】 wherein the * terminus is linked to -NR'; 【Chemistry 6】 The end is R Ａ is connected to 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof.

4. R Ａ represents F, Cl, an amino group, a cyano group, 【Chemistry 7】 Preferably, R Ａ teeth 【Chemistry 8】 More preferably, 【Chemistry 9】 That is, A compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.

5. A compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof, 【Chemistry 10】 Among them, R １Ａ and R ２Ａ are the same or different and each independently represent a hydrogen atom or R Ａ and R ３Ａ is R Ａ and R ａ , R ｂ , R ｃ , R ｄ , R Ｘ１ , R Ｘ２ , R Ｘ３ , R' and R Ａ is as defined in claim 2, 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof.

6. A compound represented by general formula (VI') or a pharmaceutically acceptable salt thereof, 【Chemistry 11】 Among them, Q is CR ５Ａ , N and N ＋ -O － Selected from R ５Ａ is R １Ａ and R １Ａ , R ２Ａ , R', R ａ , R ｂ , R ｃ , R ｄ , R Ｘ１ , R Ｘ２ , R Ｘ３ , R ３ , R ４ and R ５ is as defined in claim 5, 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof.

7. R ３ is a hydrogen atom, C １－６ Alkyl group, OR ２３ and C(O)OR ２３ Selected from R ２３ is as defined in general formula (I), and / or R ４ is a hydrogen atom, and preferably, R ３ is a hydrogen atom, a hydroxy group, C １－６ Alkyl group, C １－６ Alkoxy group, deuterated C １－６ Alkoxy group, —O-3 to 6-membered cycloalkyl group and C(O)OR ２３ Selected from R ２３ is C １－８ alkyl group, and / or R ４ is a hydrogen atom, and more preferably, R ３ represents a hydrogen atom, a methyl group, an ethyl group, a hydroxy group, a methoxy group, a cyclopropyl group, 【Chemistry 12】 and / or R ４ is a hydrogen atom, and most preferably, R ３ and R ４ are both hydrogen atoms, A compound according to any one of claims 1 to 3, 5 and 6, or a pharmaceutically acceptable salt thereof.

8. R ５ is a hydrogen atom, C １－６ Alkyl group, OR ２３ , 3- to 6-membered cycloalkyl groups and C(O)OR ２３ Selected from R ２３ is as defined in claim 1, preferably R ５ represents a hydrogen atom, a hydroxy group, C １－６ Alkyl group, C １－６ Alkoxy group, deuterated C １－６ Alkoxy group, —O-3 to 6-membered cycloalkyl group and C(O)OR ２３ Selected from R ２３ is C １－８ is an alkyl group, and more preferably, R ５ is a hydroxy group or C １－６ is an alkoxy group, and most preferably R ５ is a hydroxy group or a methoxy group; A compound according to any one of claims 1 to 3, 5, 6 and 7, or a pharmaceutically acceptable salt thereof.

9. R ５ represents a hydrogen atom, a methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group, -O-cyclopropyl, 【Chemistry 13】 Preferably, R ５ is selected from a hydrogen atom, a methyl group, a hydroxy group, a methoxy group, a deuterated methoxy group and -O-cyclopropyl; A compound according to any one of claims 1 to 3 and 5 to 8, or a pharmaceutically acceptable salt thereof.

10. R ａ is C １－６ is an alkyl group, preferably R ａ is CH ３ That is, 10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof.

11. R ｂ Halo C １－６ is an alkyl group, preferably R ｂ is CF ３ That is, 11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof.

12. R ｃ is a hydrogen atom, and R ｄ is C １－６ is an alkyl group, preferably R ｃ is a hydrogen atom, and R ｄ is CH ３ That is, 12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof.

13. R' is a hydrogen atom; 13. The compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof.

14. R Ｘ１ is a hydroxy group, C １－６ is selected from an alkoxy group and a 3- to 6-membered cycloalkyloxy group, and preferably R Ｘ１ is a hydroxyl group, a methoxy group, and 【Chemistry 14】 More preferably, R Ｘ１ is a methoxy group, 14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof.

15. R Ｘ２ is halogen, preferably R Ｘ２ is a fluorine atom, 15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof.

16. R Ｘ３ is halogen, preferably R Ｘ３ is a fluorine atom, 16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof.

17.

15. 【Chemistry 16】 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemical 21】 is selected from the compounds The compound or a pharmaceutically acceptable salt thereof.

18. A compound represented by general formula (VI'A) or a salt thereof, 【Chemical 22】 Among them, Q and R １Ａ , R ２Ａ , R', R ａ , R ｂ , R ｃ , R ｄ , R Ｘ１ , R Ｘ２ and R Ｘ３ is as defined in claim 6, 2. A compound of formula (I) according to claim 1 or a medicamentable salt thereof.

19.

23. 【Chemistry 24】 【Chemistry 25】 is selected from the compounds The compound or a pharmaceutically acceptable salt thereof.

20. A method for preparing a compound of general formula (I) or a pharmaceutically acceptable salt thereof, comprising: 【Chemical 26】 The method comprises subjecting a compound represented by general formula (Ia) or a salt thereof to a condensation reaction with a compound represented by general formula (Ib) or a salt thereof to obtain a compound represented by general formula (I) or a medicamentable salt thereof, wherein: R １０ is a halogen (preferably a chlorine atom) or OH, Ring A, R Ａ , R', R ａ , R ｂ , R ｃ , R ｄ , R ｅ , X, X １ , X ２ , X ３ , X ４ , X ５ and r are as defined in claim 1; method.

21. A method for preparing a compound of general formula (VI') or a pharmaceutically acceptable salt thereof, comprising: 【Chemical 27】 A compound represented by general formula (VI'A) or a salt thereof and NH ２ -R ５ or a salt thereof (preferably hydrochloride) to obtain a compound represented by general formula (VI') or a pharmaceutically acceptable salt thereof, R ３ and R ４ are both hydrogen atoms, R', R ａ , R ｂ , R ｃ , R ｄ , R Ｘ１ , R Ｘ２ , R Ｘ３ , R １Ａ , R ２Ａ , Q and R ５ is as defined in claim 6, method.

22. 18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients. Pharmaceutical compositions.

23. Use of a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 22, in the preparation of a medicament for inhibiting a voltage-gated sodium channel, preferably wherein the voltage-gated sodium channel is Nav1.

8. use.

24. Use of a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 22, in the preparation of a medicament for treating and / or alleviating pain and pain-related disorders, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia, wherein the pain is preferably selected from chronic pain, acute pain, inflammatory pain, cancer pain, post-operative pain, neuropathic pain, musculoskeletal pain, primary pain, intestinal pain and idiopathic pain, and the post-operative pain is preferably selected from bunionectomy pain, herniorrhaphy pain and abdominoplasty pain. use.

Images